This Work Programme was adopted on 10 December 2013. The parts that relate to 2015 (topics, dates, budget) have, with this revised version, been updated. The changes relating to this revised part are explained on the Participant Portal.
Personalising health and care

Understanding health, ageing and disease

PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

PHC 2 – 2015: Understanding diseases: systems medicine

PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities

Effective health promotion, disease prevention, preparedness and screening

PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions

PHC 5 – 2014: Health promotion and disease prevention: translating ‘omics’ into stratified approaches

PHC 6 – 2014: Evaluating existing screening and prevention programmes

PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens (see also societal challenge 2)

PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis


Improving diagnosis


PHC 11 – 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies

PHC 12 – 2014/2015: Clinical research for the validation of biomarkers and/or diagnostic medical devices

Innovative treatments and technologies

PHC 13 – 2014: New therapies for chronic non-communicable diseases

PHC 14 – 2015: New therapies for rare diseases

PHC 15 – 2014/2015: Clinical research on regenerative medicine

PHC 16 – 2015: Tools and technologies for advanced therapies

PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly

PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population

Advancing active and healthy ageing
PHC 19 – 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments ................................................................. 29
PHC 20 – 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment ................................................................. 30
PHC 21 – 2015: Advancing active and healthy ageing with ICT: Early risk detection and intervention ................................................................................................................... 31
PHC 22 – 2015: Promoting mental wellbeing in the ageing population ........................................... 32
Integrated, sustainable, citizen-centred care .................................................................................. 33

PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems: ................................................................. 33
PHC 24 – 2015: Piloting personalised medicine in health and care systems ................................ 34
PHC 25 – 2015: Advanced ICT systems and services for Integrated Care .................................. 35
PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth ....... 37
PHC 27 – 2015: Self-management of health and disease and patient empowerment supported by ICT .................................................................................................................. 40
PHC 28 – 2015: Self-management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself ........................................ 42
PHC 29 – 2015: Public procurement of innovative eHealth services ......................................... 43

Improving health information, data exploitation and providing an evidence base for health policies and regulation ........................................................................................................ 45

PHC 30 – 2015: Digital representation of health data to improve disease diagnosis and treatment ................................................................. 45
PHC 31 – 2014: Foresight for health policy development and regulation ..................................... 46
PHC 32 – 2014: Advancing bioinformatics to meet biomedical and clinical needs ................. 47
PHC 33 – 2015: New approaches to improve predictive human safety testing ....................... 49
PHC 34 – 2014: eHealth interoperability .................................................................................... 50
CONDITIONS FOR THIS CALL ................................................................................................. 54

Co-ordination activities ........................................................................................................... 63

HCO 1 – 2014: Support for the European Innovation Partnership on Active and Healthy Ageing .................................................................................................................. 63
HCO 2 – 2014: Joint Programming: Coordination Action for the Joint Programming Initiative (JPI) "More Years, Better Lives - the Challenges and Opportunities of Demographic Change" ................................................................. 64
HCO 4 – 2014: Support for international infectious disease preparedness research .............. 66
HCO 6 – 2015: Global Alliance for Chronic Diseases. Prevention and treatment of lung diseases ................................................................................................................. 70
HCO 7 – 2014: ERA-NET: Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020 ................................................................. 74

HCO 8 – 2014: ERA-NET: Aligning national/regional translational cancer research programmes and activities ........................................................................................................ 76

HCO 9 – 2014: ERA-NET: Systems medicine to address clinical needs ............................................. 77

HCO 10 – 2014: ERA-NET: Rare Disease research implementing IRDiRC objectives ................... 79

HCO 11 – 2015: ERA-NET: Collaboration and alignment of national programmes and activities in the area of brain-related diseases and disorders of the nervous system ................................. 80

HCO 12 – 2015: ERA-NET: Antimicrobial Resistance ..................................................................... 81

HCO 13 – 2015: ERA-NET: Cardiovascular disease ......................................................................... 83

HCO 14 – 2014: Bridging the divide in European health research and innovation ......................... 85

HCO 15 – 2014: Mobilisation and mutual learning action plan ......................................................... 86

HCO 16 – 2014: National Contact Points ....................................................................................... 86

HCO 17 – 2015: Towards sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases ................................................................. 88

CONDITIONS FOR THIS CALL ........................................................................................................ 90

Fast track to innovation pilot .......................................................................................................... 93

Other actions ................................................................................................................................ 94


HOA 2 – 2014/2015: Tenders for programme evaluation, studies and impact assessment,
Scientific Panel for Health, and for conferences, events and outreach activities ......................... 94

HOA 3 – 2014/2015: Presidency events - eHealth .......................................................................... 95

HOA 4 – 2014/15: Independent experts assisting in proposal evaluations and assessment, and
project reviews ................................................................................................................................ 95

HOA 5 – 2014: Grant to the Global Alliance for Chronic Diseases .................................................. 95

HOA 6 – 2014: Stem cell research outreach ..................................................................................... 96

HOA 7 – 2015: eHealth Inducement Prize: Food scanner ............................................................... 98

HOA 8 – 2015: Inducement Prize: An innovative test to reduce the use of antibiotics in the
management of upper respiratory tract infection ......................................................................... 99

Budget ........................................................................................................................................... 101
**Introduction**

The Horizon 2020 societal challenge of ‘health, demographic change and wellbeing’ (SC1) for the years 2014 and 2015 includes 34 topics in the ‘personalising health and care’ focus area call (15 in 2014 only, 17 in 2015 only and 2 which are open in both years) and 16 topics in the ‘co-ordination activities’ call (11 in 2014 and 5 in 2015). 8 other actions designed to support the implementation of the challenge are also included and are not subject to competitive calls for proposals. The total budget available is approximately EUR 1.21bn.

The choice to focus on personalising health and care is informed by the ageing of the European population, an increasing communicable and non-communicable disease burden and the fall-out from the economic crisis. In combination, these factors are jeopardising the sustainability and equity of European health and care systems, on which Europe already spends nearly 10% GDP.

The personalising health and care call aims to create opportunities for real breakthrough research and radical innovation in response to these challenges, by supporting the translation of findings into the clinic and other health and care settings to improve health outcomes, reduce health inequalities and to promote active and healthy ageing.

Topics in the call are divided into 7 areas which reflect the need for a translational and integrated approach to the challenge, providing support both to longer and mid-term research as well as to shorter term innovation activities. Topics in the areas of ‘understanding health…’ and ‘improved health information and data exploitation’ provide underpinning, longer term support to topics in the areas of ‘prevention…’, ‘diagnosis…’, ‘treatment…’, ‘advancing active and healthy ageing’ and ‘delivering integrated, sustainable and citizen centred care’.

Taken together, work to be supported by these topics will improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease; improve our ability to monitor health and to prevent, detect, treat and manage disease; support older persons to remain active and healthy; and test and demonstrate new models and tools for health and care delivery. In doing so, support will be provided to research and innovation performers, including significant, tailored support to small and medium sized enterprises, in particular through topic PHC 12 which makes use of the new SME instrument.

Societal challenge 1 is also implemented by the continuation and extension of a variety of activities not included in this work programme, the innovative medicines initiative\(^1\) (IMI), the European and developing countries clinical trials partnership\(^2\) (EDCTP) and the active and

---

1. [http://www.imi.europa.eu/content/documents#horizon_2020](http://www.imi.europa.eu/content/documents#horizon_2020)
2. [http://www.edctp.org/Towards_EDCTP2.799.0.html](http://www.edctp.org/Towards_EDCTP2.799.0.html)
assisted living programme\(^3\) (AAL). Topics in this work programme also respond to the priorities of the European Innovation Partnership on Active and Healthy Ageing\(^4\) (EIP-AHA). Further appropriate stakeholder and public engagement will be organised.

A novelty in Horizon 2020 is the Open Research Data Pilot which aims to improve and maximise access to and re-use of research data generated by projects. While other Work Programme parts (not SC1) and areas have been explicitly identified as participating in the Pilot on Open Research Data, individual actions funded under the other Horizon 2020 parts and areas may choose to participate in the Pilot on a voluntary basis. The use of a Data Management Plan is required for projects participating in the Open Research Data Pilot. Further guidance on the Open Research Data Pilot and is made available on the Participant Portal.


Personalising health and care

H2020-PHC-2014/2015

Proposals are invited against the following topics:

Understanding health, ageing and disease

PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

Specific challenge: The development and preservation of good health, and the occurrence and evolution of common diseases and disabilities result from varying degrees of interaction between the genetic make-up of individual human beings and behavioural, environmental (including endocrine disruptors), occupational, nutritional and other modifiable lifestyle factors. This applies from the earliest stages of development throughout life.

Understanding these factors, their interactions and the extent to which they contribute to health preservation and/or to disease development is important for the development of preventive and therapeutic measures supporting good health, prolonged active independence and a productive working life, not least in the context of changing demographic patterns and the ageing of the European population. In particular, proposals should contribute to improving risk identification and validation, and will allow better diagnosis, risk-based prevention strategies and policies.

Scope:

EITHER:

i. The identification of health trends and determinants, their validation, and the validation of risk factors for disease and disability, through the generation, integration and validation of data derived from relevant disciplines (e.g. molecular, behavioural, nutritional, clinical, social and environmental epidemiology; exposure sciences; genetics, epigenetics, etc.). This should involve the exploitation of existing cohorts and longitudinal studies and the assessment of the necessity to establish new ones, as well as where relevant, the valorisation of knowledge gained from population-based bio-banks.

OR:

ii. The identification of determinants and pathways characteristic of healthy and active ageing (from early stages of development onwards) and of health deterioration caused by time, disease accumulation and the abovementioned risk factors and their interactions.

In both cases, sex and gender differences should be taken into account.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected impact:

In both cases, proposals should provide a better understanding of the combined effects of factors causing health and disease, with the knowledge generated underpinning the future development of evidence based prevention, diagnostic, therapeutic and other strategies.

For option:

i. This should provide evidence for risk identification, underpinning future preventive, diagnostic and therapeutic strategies and policies

For option:

ii. This should provide a better understanding of pathways of healthy ageing, underpinning future strategies for the promotion of healthy ageing, targeted disease prevention and clinical interventions

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 2 – 2015: Understanding diseases: systems medicine

Specific challenge: The development of new, evidence-based treatments relies on an improved understanding of the often very complex pathophysiology of diseases. Systems (bio) medicine approaches have the potential to tackle this complexity through the integration of a variety of biological and medical research data and computational modelling. A European collaborative approach is required to assemble the necessary multidisciplinary expertise (e.g. biology, medicine, mathematics, computational technologies) for implementing systems (bio) medicine approaches.

Scope: Proposals should focus on new avenues for understanding the complexity of clinical phenotypes in multifactorial diseases and/or their co-morbidities. This should entail the development/optimisation and/or application of systems medicine approaches, and integration of biomedical and clinical data to produce or refine disease models using advanced statistical, computational and mathematical approaches. The predictive value of such models should be validated in well-phenotyped patient cohorts, taking due account of gender, and their clinical potential thoroughly investigated.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

- Leverage of existing investments in Europe in the field of systems biomedicine
New directions for better disease detection, prognosis and therapy development

Systems medicine tools and approaches tailored for medical research and/or the clinic, which represent an improvement over established practice.

**Type of action:** Research and innovation actions

_The conditions related to this topic are provided at the end of this call and in the General Annexes_

**PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities**

**Specific challenge:** The development of new treatments is greatly facilitated by an improved understanding of the pathophysiology of diseases. There is therefore a need to address the current knowledge gaps in disease aetiology in order to support innovation in the development of evidence-based treatments. In this context, a better understanding of the mechanisms that are common to several diseases, in particular of those leading to co-morbidities, constitutes an important challenge.

**Scope:** Proposals should focus on the integration of pre-clinical and clinical studies for the identification of mechanisms common to several diseases. Proposals should assess and validate the relevance of these common mechanisms and of their biomarkers (where relevant) on the development of disease-specific pathophysiology, as well as their role in the development of co-morbidities in both males and females.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- A better understanding of disease pathways and / or mechanisms common to a number of diseases
- New directions for clinical research for better disease prevention, health promotion, therapy development, and the management of co-morbidities

**Type of action:** Research and innovation actions

_The conditions related to this topic are provided at the end of this call and in the General Annexes_
Effective health promotion, disease prevention, preparedness and screening

PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions

Specific challenge: Better health promotion and disease prevention interventions can make a significant contribution to equitable health improvements and thus the sustainability of health and care systems. A “health in all policies” approach has been identified as a promising means to stimulate and foster environments that support health, wellbeing and behavioural change. This requires a multi-sector approach that aims to improve health by addressing such factors as housing; water and sanitation systems; transportation; exposure to chemicals and their mixtures; communication, education and information; occupational factors, physical activity, food production and distribution, and the physical, natural and social environments.

Scope: Given the breadth of sectors, the scope of this topic is limited to the integration of environment, climate and health sectors (including but not limited to air quality, water and sanitation, chemicals, occupational factors, etc.).

Using a multidisciplinary approach and involving relevant stakeholders such as policy makers, the private sector, civil society organisations and so on, proposals should address all of the following elements:

- Develop inter-sector interventions (and/or policy initiatives) to promote health or prevent disease based on known environmental stressors. These inter-sector interventions should address key environmental stressors for which changes in relevant EU and international policies related to environment, climate and health would have the greatest impact. In the development of these interventions, age and gender aspects should be taken into account where appropriate.

- Document success characteristics of the abovementioned inter-sector interventions, including those factors that help to overcome barriers to inter-sector co-operation; contextual factors such as the interplay between politics and economics should be addressed;

- Assess these inter-sector interventions for their health, economic and social benefits and their impact on reducing inequalities.

In line with the Union’s strategy for international cooperation in research and innovation⁵, research activities should be developed as a European contribution to and collaborate with existing international activities and those under development.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.

⁵ COM(2012)497
Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:
- On the basis of quantitative and qualitative indicators, evidence on effective interventions taking a ‘health in all’ approach, linking environment, climate and health, allowing informed decisions on multi-sector interventions and related policies.
- Impact on health and care systems and other public services in terms of their sustainability,
- Contribution to the EU commitment to the Rio+20 agenda and the new UN Sustainable Development Goals (SDGs), as well as to the Parma declaration 2010.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 5 – 2014: Health promotion and disease prevention: translating ‘omics’ into stratified approaches**

**Specific challenge:** ‘Omics’ research (including but not limited to genomics, epi-genomics, meta-genomics and proteomics) is moving at a breath-taking pace. A major challenge for the next decade is to determine when and how this wealth of ‘omics’ information can be usefully applied by both the public and private sectors for the development of personalised /stratified approaches in health promotion and disease prevention.

**Scope:** Proposals should address all of the following elements:

Develop and assess a personalised / stratified health promotion or disease prevention programme, taking into account the ‘omics’ characteristics of individuals, complemented by environmental and/or lifestyle factors;

Include the development of tools and methods for the use of ‘omics' data in such programmes;

Include a multi-disciplinary approach to assess the validity and utility of ‘omics’ data in preventive medicine or in prevention programmes targeting specific population groups. This should include:

- The assessment of the predictive value of such programmes in identifying at-risk groups throughout their lives, as compared with conventional methods;
- The assessment of the usefulness of ‘omics’ data for improving the health of individuals or populations;
- The assessment should include account age and gender aspects where appropriate.
The assessment of the behavioural, ethical, legal, regulatory and social implications, as well as of the cost-effectiveness of the programme;

Include risk-benefit communication to various groups involved in such a programme, including individuals, policy makers and regulators.

Preference will be given to proposals focusing on diseases with either high prevalence or which present a high risk to the individual, or a high cost to society.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Evidence on the validity, utility and cost-effectiveness of ‘omics’ based health promotion and disease prevention programmes, allowing informed decisions on the organisation of health and care systems.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 6 – 2014: Evaluating existing screening and prevention programmes**

**Specific challenge:** Some existing population based screening and disease prevention programmes have not been assessed for their effectiveness, or vary in terms of their application within and across countries throughout Europe. This may result in inappropriate interventions, delayed provision of the correct treatment, increased disease burden, health inequities and increased costs for health and care systems.

Such programmes therefore need systematic evaluation for their impact on health outcomes, cost effectiveness and health equity.

**Scope:** Proposals should assess existing screening and disease prevention strategies and programmes, on the basis of health outcomes, quality-of-life, equity and cost-effectiveness and ethical considerations, at the level of the individual or stratified population groups and across Europe. The gender dimension should be taken into account where relevant.

Comparison between different countries and regions, demographic groups and cultures should be made in order to identify specific contextual links as well as to identify opportunities for exchange of knowledge and experience between countries and regions.

Proposals should include the development of new methods or the adaptation of existing ones for this type of assessment. These methods and tools (including self-assessment tools) should
be applied in different health systems and organisational infrastructures to test their applicability in different political, economic and societal contexts.

Due attention should be paid from the outset to the further development and dissemination of methodological expertise, including capacity building across Europe, in order that the expertise generated is fully exploited.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Evidence for the increased use, or discontinuation of, existing screening and prevention programmes allowing informed decisions by policymakers
- Capacity building in the assessment of such screening and prevention programmes
- Improved health outcomes, greater health equity and cost effectiveness based on the implementation of effective screening and prevention programmes.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens (see also societal challenge 2)**

**Specific challenge:** Human and animal health worldwide is increasingly threatened by potential epidemics caused by existing, new and emerging infectious diseases (including from antimicrobial resistant pathogens), placing a burden on health and veterinary systems, reducing consumer confidence in food, and negatively affecting trade, food chain sustainability and food security.

The increasing incidence and more rapid spread of such diseases are facilitated by modern demographic, environmental, technological, economic and societal conditions. Many of these infections are zoonoses, necessitating an integrated, cross-border, ‘one health’ approach to research and public health measures in the human and veterinary field, including the food chain.

**Scope:** Sequence based data of pathogens should be generated, stored and analysed in combination with clinical, microbiological, epidemiological, additional gene-
transcriptome-based analyses and other data (e.g.: differing responses in women and men) for risk assessment (RA) in an appropriate information system for all sectors (public health, food, animal health).

Proposals should improve pathogen monitoring by rapid identification, comparison, and geographical mapping, including bio-tracing approaches. Proposals should include predictive models on RA, to identify ‘high-risk’ areas and disease-emergence patterns. Proposals should ensure links and consistency with existing networks and databases (TESSY, RASFF, EWRS, EFSA/ECDC\textsuperscript{6} molecular testing database) and data protection requirements. Access to the system should be granted to relevant animal, food safety and human health service stakeholders.

Harmonised standards for sampling, sequencing, sex-disaggregated representative (meta-) data collection, management and sharing should be developed. Likewise, better management tools for authorities, businesses and citizens and risk communication tools for authorities should be developed. The cost effectiveness of the tools and methods should be assessed. Better understanding of outbreaks in regions with little or no surveillance systems, mass migration settings or post-disaster settings may require special attention for emerging and re-emerging pathogens. Proposals should cooperate with existing EU projects and international activities and those under development.

The Commission considers that proposals requesting a contribution from the EU of between EUR 15 and 20 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Better containment and mitigation of epidemics by competent authorities on the basis of a shared information system and global standards for rapid pathogen identification.
- Consequent improved resource efficiency and reduction of economic impact of outbreaks (related to health care costs, market losses); facilitation of international trade, increasing competitiveness of European food and agricultural sector; reinforcement of food chain sustainability and enhancement of food security, reduced carbon footprint.

\textsuperscript{6} TESSY = The European surveillance system  
RASFF = Rapid Alert System for Food and Feed  
EWRS = Early Warning and Response System  
EFSA = European Food Safety Authority  
ECDC = European Centre for Disease Prevention and Control
In line with the Union’s strategy for international cooperation in research and innovation, proposals should contribute to implementing the ‘Global Research Collaboration for Infectious Disease Preparedness’ and its objectives.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis

Specific challenge: Vaccines offer a safe and cost-effective way to protect large populations against infectious diseases, or at least to mitigate the clinical course of these diseases. Yet many poverty-related and neglected infectious diseases continue to escape attempts to develop effective vaccines against them.

Disappointing results of recent clinical trials point to bottlenecks in identifying viable candidate vaccines, which if unaddressed will continue to present significant risks of failure at relatively late stages of the development process.

The specific challenge will be to shift this ‘risk curve’ in order better to select successful vaccine candidates (and discard those with a higher risk of failure) at an earlier stage of the vaccine development process.

Scope: Proposals should focus on strengthening the capacity for discovery and early development of new vaccine candidates for tuberculosis by addressing all of the following inter-related elements:

1. Establishment of a platform for the identification of several new diverse and novel vaccine candidates for tuberculosis, and their pre-clinical and early clinical testing.

2. The major bottlenecks in vaccine development should be addressed; in particular better ways for early distinction between successful candidates and those that will eventually fail in late stage clinical trials. Proposals should therefore address areas such as in vitro and in silico testing, predictive animal models, predictive correlates of protection, phase 0 trials, first in man trials and innovative risk prediction methods, taking into account potential sex-specific differences. Based on specific gating and priority setting criteria the most promising new vaccine candidates for tuberculosis should be compared with other candidates and selected in an objective and transparent process according to their merits in line with effective vaccine portfolio management.

---

7 COM(2012)497
3. The successful proposal shall be part of the Global TB Vaccine Partnership and continue its vaccine development in the context of this initiative in collaboration with the European and Developing Countries Clinical Trials Partnership (EDCTP), and a pathway and commitment towards this must form an integral part of the proposal.

In line with the Union’s strategy on international cooperation\(^8\) in research and innovation, international cooperation is encouraged. The proposals should also address the barriers and possible facilitators regarding the uptake and implementation of a new vaccine in low, middle and high income countries in different regions of the world.

The Commission considers that proposals requesting a contribution from the EU of between EUR 15 and 25 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Reduction in the cost associated with late stage vaccine failure, increasing the number of other candidates which can be tested with the same resources, thus increasing the chance of discovery of an effective vaccine

- Contribution to the implementation of the Global TB Vaccine Partnership for the development of tuberculosis vaccines and, (currently under development in collaboration with European Investment Bank and Bill and Melinda Gates Foundation) including the establishment of close links with the European and Developing Countries Clinical Trials Partnership (EDCTP).

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS**

**Specific challenge:** Vaccines offer a safe and cost-effective way to protect large populations against infectious diseases, or at least to mitigate the clinical course of these diseases. Furthermore, they may in combination with other treatment modalities contribute to an eradicative cure for HIV. Many poverty-related and neglected infectious diseases however continue to escape attempts to develop effective vaccines against them.

\(^8\) COM(2012)497
Disappointing results of recent clinical trials point to bottlenecks in identifying viable candidate vaccines, which if unaddressed will continue to present significant risks of failure at relatively late stages of the development process.

The specific challenge will be to shift this ‘risk curve’ in order to better select successful vaccine candidates (and discard those with a higher risk of failure) at an earlier stage of the vaccine development process, for preventive as well as therapeutic vaccines.

**Scope:** Proposals should focus on strengthening the capacity for discovery and early development of new vaccine candidates for HIV/AIDS by addressing all of the following inter-related elements:

1. Establishment of a platform for the discovery and selection of several new diverse and novel preventive or therapeutic vaccine candidates for HIV/AIDS, and their pre-clinical and early clinical testing.

2. The major bottlenecks in vaccine development should be addressed; in particular better ways for early distinction between successful candidates and those that will eventually fail in late stage clinical trials. Proposals should therefore pool expertise in the areas of in vitro and in silico testing, predictive animal models, predictive correlates of protection, phase 0 trials, first in man trials and innovative risk prediction methods, taking into account sex-specific differences. Based on these criteria the most promising new vaccine candidates for HIV/AIDS will be compared and selected in an objective and transparent process according to their merit.

3. The successful proposal shall continue its vaccine development in the context of the European and Developing Countries Clinical Trials Partnership (EDCTP), and a pathway and commitment towards this direction must form an integral part of the proposal. It shall also ensure collaboration with other EU-funded research actions in related research fields.

In line with the Union’s strategy on international cooperation in research and innovation, international cooperation is encouraged. The proposals should also address the barriers and possible facilitators regarding the uptake and implementation of a new vaccine in low, middle and high income countries in different regions of the world.

The Commission considers that proposals requesting a contribution from the EU of between 15 and 20 million euro would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Reduction in the cost associated with late stage preventive or therapeutic vaccine failure, increasing the number of other candidates which can be tested with the same resources, thus increasing the chance of discovery of an effective vaccine

---

9 COM(2012)497
Establishment of close links with the European and Developing Countries Clinical Trials Partnership (EDCTP), for the further clinical development of the vaccine candidates identified in the present initiative.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

Improving diagnosis


Specific challenge: The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving and often complex technologies.

Improved clinical decisions based on new and improved diagnostic tools and techniques should lead to better health outcomes while contributing to the sustainability of the health care system.

This is also a field where many small European companies are active.

Scope: Proposals should focus on the development and application of novel in vitro diagnostic tools and technologies (including assays and platforms). The novel application of existing tools and technologies is not included. These tools and technologies should improve the performance of diagnosis, prediction, monitoring, intervention or assessment of therapeutic response, with a significant impact on clinical decisions and health outcomes.

Additionally, proposals may include approaches based on high-throughput screening, nanotechnologies or microfluidics, data analysis methodology, or technologies for point-of-care diagnostics.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

- Innovative, more accurate, more reliable and cost effective in vitro diagnostic tools and technologies for earlier disease diagnosis, patient stratification and/or prognosis of disease outcome leading to improved clinical decisions and health outcomes.
• Contribution to the sustainability of health care systems.
• Growth of the European diagnostics sector, in particular for SMEs.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 11 – 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies

Specific challenge: The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving, and often complex technologies.

Improved clinical decisions based on new and improved diagnostic tools and techniques should lead to better health outcomes while contributing to the sustainability of the health care system.

This is also a field where many small European companies are active.

Scope: Proposals should focus on the development of innovative in vivo imaging tools and technologies. The novel application of existing tools and technologies is not included. Tools and technology should aim at improving diagnosis, prediction, monitoring, image-based intervention or assessment of therapeutic response, with a significant impact on clinical decisions and health outcomes. Proposals should focus on innovations that offer a clear advantage over existing tools and technologies. Development of in vivo medical imaging technologies should make use of existing high-tech engineering or physics solutions or innovative ideas and concepts coming from those fields and if appropriate, new developments in the field of imaging agents.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

• New in vivo diagnostic tools and methods providing more accurate, less invasive, more reliable and earlier disease diagnosis, prediction or response to therapy, leading to improved clinical decisions and outcomes.
• Contribution to the sustainability of health care systems.
- Growth of the European diagnostics sector, in particular for SMEs.

**Type of action**: Research and innovation actions

**The conditions related to this topic are provided at the end of this call and in the General Annexes**

**PHC 12 – 2014/2015: Clinical research for the validation of biomarkers and/or diagnostic medical devices**

**Specific challenge**: Biomarkers are used in clinical practice to describe both normal and pathological conditions. They can also have a prognostic or a predictive power. They are therefore increasingly used in medicine and many potential biomarkers are proposed every year.

Only a few of them are however validated for use in a clinical research setting. Such validation implies the demonstration of a link to a pertinent clinical endpoint or process, as well as a robust and appropriate analytical method.

The clinical validation of biomarkers will be increasingly important for the development of new diagnostics, and this is a research area where many small European companies are active.

Improved clinical decisions should lead to better health outcomes while contributing to the sustainability of the health care system.

**Scope**: The SME instrument consists of three separate phases and a coaching and mentoring service for beneficiaries. Participants may apply to phase 1 with a view to applying to phase 2 at a later date, or directly to phase 2.

Proposals submitted to phase 1 shall consist of a draft business plan and feasibility study verifying the technological/practical and economic viability of the clinical validation proposed. These may, for example, comprise risk assessment, market study, user involvement, intellectual property (IP) management, innovation strategy development, partner search, feasibility of concept etc. Proposals may analyse bottlenecks preventing advance of the applicant SME in this area and identify how a phase 2 proposal may contribute to attaining growth or sustainability.

The main outcome of the proposal should be a detailed business plan. Funding for phase 1 will be provided in the form of a lump sum of EUR 50,000 and proposals should have a duration of around 6 months.

In phase 2 proposals should address the specific challenge described, elaborated in the scope section above, and demonstrate high potential in terms of applicant's competitiveness and growth underpinned by a strategic business plan.
Proposals shall be based on a business plan developed either through phase 1 or another means. Particular attention must be paid to IP protection and ownership; applicants should provide evidence of the possibility of commercial exploitation (‘freedom to operate’).

The clinical validation of existing potential biomarkers (not the identification of new ones) is sought. This validation should provide evidence for: high analytical validity; appropriate sensitivity and specificity; clinical validity/utility. Preference will be given to validation of biomarkers with high potential for short term uptake into clinical practice.

In addition, validation of the clinical performance of new diagnostic devices can be supported, either in combination with the biomarker validation, or against existing standards.

Both in vivo and in vitro potential biomarkers are eligible. Preference will be given to the validation of disease related biomarkers (i.e. diagnostic, susceptibility/risk, monitoring and prognostic biomarkers).

Proposals shall contain a specification for the outcome of the project, including a first commercialisation plan, and criteria for success.

The Commission considers that phase 2 proposals requesting a contribution from the EU of between EUR 1 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Phase two projects should duly justify their duration making reference to obtaining patient samples, ensuring patient follow up, etc.

In addition, in phase 3, SMEs can benefit from indirect support measures and services as well as access to the financial facilities supported under Access to Risk Finance of this work programme.

Successful beneficiaries will be offered coaching and mentoring support during phase 1 and phase 2. This service will be accessible via the Enterprise Europe Network (EEN) and provided by a dedicated coach through consultation to the beneficiaries. The coaches will be recruited from a database managed by the Commission and on the basis of their business experience and competencies. Throughout the three phases of the instrument, the EEN will complement coaching support by providing access to its innovation and internationalisation services. This may include, for example, depending on the needs of the SME, support in identifying growth potential, developing a growth plan and maximising it through internationalisation; strengthening the leadership and management skills of individuals in the senior management team and developing in-house coaching capacity; developing a marketing strategy or raising external finance.

Expected impact: This should provide:

- Increased clinical availability and exploitation of biomarkers for the benefit of the patient.
- New diagnostic devices.
- Facilitation of entry of improved diagnostics in the clinic and the market.

- Support for the implementation of the Commission proposal for a revised in vitro diagnostic devices regulation\(^{10}\).

- Enhancing profitability and growth performance of SMEs by combining and transferring new and existing knowledge into innovative, disruptive and competitive solutions seizing European and global business opportunities.

- Contribution to the sustainability of health care systems.

- Increased likelihood of market uptake and distribution of resulting innovations tackling the abovementioned specific challenge(s) in a sustainable way.

- Leveraging of private investment in clinical validation as described above, notably leverage of private co-investor and/or follow-up investments.

**Type of action:** SME instrument (100% funding)

While all other instances of the use of the SME instrument in Horizon 2020 provide for reimbursement at 70%, the predominance of research type activities in clinical validation necessitate reimbursement at 100% in this case.

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**Innovative treatments and technologies**

**PHC 13 – 2014: New therapies for chronic non-communicable diseases**

**Specific challenge:** Chronic non-communicable diseases represent a significant burden on individuals and healthcare systems. Innovative, cost effective therapeutic approaches are required to provide the best quality of care when prevention fails. While a considerable amount of knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

**Scope:** Clinical trial(s) supporting proof of concept in humans to assess the potential clinical efficacy of the novel therapeutic concept(s) and / or optimisation of available therapies (e.g. drug repurposing). The application may build on pre-existing pre-clinical research and additional results from large scale databases. A concise feasibility assessment justified by available published and preliminary results and supporting data should also be provided.

---

Considerations of effectiveness and potential clinical benefit (possibly including real world data) should be integrated in the application if relevant.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

- New therapeutic strategies, adapted where relevant to the differing needs of men and women, with the highest potential to generate advances in clinical practice for chronic diseases, including multi- or comorbidity, ready for further development.

- Early exclusion of candidate strategies unlikely to succeed.

- Contribute to the improvement of the therapeutic outcome of major chronic health issues with significant impact on burden of diseases both for individual patients and for health care systems.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 14 – 2015: New therapies for rare diseases

Specific challenge: A considerable amount of knowledge has been generated by biomedical research in recent years, yet most of the 6000-8000 rare diseases are lacking therapies despite many diseases being life-threatening or chronically debilitating.

Specific problems posed in therapy development for rare diseases include the small and dispersed patient populations\(^{11}\) and the nature of the therapies proposed which are often highly specialised and novel requiring the advice of regulatory authorities during development. In addition the limited market for such therapies provides a low commercial return.

Scope: Proposals may address one or more of the following: development of new or improved therapeutic approaches, for repurposing of existing therapies, as well as for preclinical research, animal model development and good manufacturing practice (GMP) production.

Proposed treatments to be developed may range from small molecule to gene or cell therapy.

Clinical trials shall only be supported in cases where "orphan designation" has been given by the European Commission and where the proposed clinical trial design takes into account recommendations from protocol assistance given by the European Medicines Agency and where a clear patient recruitment strategy is presented. The orphan medicinal product must have been granted the EU orphan designation\textsuperscript{12} at the latest on the date of the Stage 2 call closure. A concise feasibility assessment justified by available published and preliminary results and supporting data shall also be provided. Considerations of effectiveness / potential clinical benefit should be integrated in the application if relevant.

Selected proposals should contribute to the objectives of, and follow the guidelines and policies of the International Rare Diseases Research Consortium, IRDiRC\textsuperscript{13}.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** This should provide:

- Advancing the development of new therapeutic options for patients living with rare diseases.
- In line with the Union’s strategy for international cooperation in research and innovation\textsuperscript{14}, proposals should contribute towards IRDiRC objectives.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

---

**PHC 15 – 2014/2015: Clinical research on regenerative medicine**

**Specific challenge:** Translating basic knowledge on regenerative medicine into the clinic is held up by the difficulty in undertaking ‘first in man’ studies. Specific research is needed for proving safety, efficacy and repeatability of new treatments. The, very often iterative, dialogue between the relevant authorities and those developing regenerative medicine approaches is needed before specific regulatory requirements can be established.


\textsuperscript{13} www.irdirc.org

\textsuperscript{14} COM(2012)497
As a new therapeutic field lacking established business models, financing is a particular obstacle to clinical-stage research in regenerative medicine. The challenge is to initiate a specific action to overcome this hurdle to in-patient research and to determine the potential of new regenerative therapies.

**Scope:** Proposals should focus on regenerative medicine therapies which are ready for clinical (in-patient) research. Proposals should have at the time of proposal submission the necessary ethical and regulatory authorisations to carry out the work or provide evidence of regulatory engagement and that such approval is close. Preference will be given to proposals which have or are closest to having approvals in place for clinical work to start. Since the objective is to test new regenerative therapies, proposals may address any disease or condition but a justification for the choice must be provided. Clinical work should represent a central part of the project.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Obtain results of in-patient regenerative medicine research so that new therapies can be taken to the next level of testing or, if not successful, can be discarded.
- Stimulate growth and competitiveness of European regenerative medicine including European small and medium sized enterprises and industry operating in the sector.
- Increase the attractiveness of Europe as a location of choice to develop new therapeutic options.
- Lever existing investments in fundamental research in regenerative medicine.
- New approaches to currently untreatable diseases.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 16 – 2015: Tools and technologies for advanced therapies**

**Specific challenge:** For their successful application, new therapies, such as gene or cell therapies, tissue engineering or regenerative medicine often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient.
In particular, achieving therapeutic scale production and GMP standards at reasonable cost is often underestimated. In addition, specific attention needs to be given to aspects such as miniaturisation, automation, biomaterials and scaffold construction while advanced methods and devices for targeted and controlled delivery, and monitoring technology, are needed to bring these innovative treatments to the patient.

Since experience with the new therapies is by definition limited, achieving regulatory compliance for them is another challenge.

Scope: The term advanced therapies encompasses gene therapy, cell therapy, tissue engineering, regenerative medicine and bio-artificial organs. These are biological approaches to therapy which often share common technologies.

Proposals should focus on refining a particular technological step or component needed by the therapeutic approach.

Establishing proof-of-concept for the new technology and carrying out preclinical research may be included if needed.

Regulatory aspects of the new technology should be addressed as appropriate.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Development of tools and technologies enabling establishment of new therapies or patient interventions
- Supporting regulatory compliant new technologies
- Boost the growth and the competitiveness of the European medical technology sector
- Combine new technology developments from different sectors for better, safer and customer friendly products
- Increase the attractiveness of Europe as a hub for innovative medical technologies

Type of action: Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly**

Specific challenge: Effective health care for the rapidly growing elderly population in Europe is challenging and complex. This population is subject to frequent and numerous comorbidities, associated poly-pharmacy and impaired hepatic and renal function, as well as
problems linked to access to care and compliance. In addition, while the elderly are overrepresented in terms of patient numbers, this group is underrepresented or even excluded from many clinical trials that generate the evidence-base for health care interventions.

Scope: Proposals should compare the use of currently available (pharmacological as well as non-pharmacological) healthcare interventions in the elderly (> 65 year) population (or subgroups thereof).

While there is no restriction on the diseases or interventions to be the focus of proposals, preference will be given to proposals focusing on interventions with high public health relevance, i.e. interventions addressing conditions that are particularly frequent, have a high negative impact on the quality of life of the individual and/or are associated with significant costs or where savings can be achieved.

Issues of particular relevance for the target populations, for example, poly-pharmacy, vaccine efficacy, compliance, and under-diagnosed or untreated pain should be taken into account. Given the focus on existing interventions, proposals will aim to contribute to decisions about the discontinuation of interventions that are less effective or cost-effective than others.

A comprehensive array of clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, morbidity, costs, and performance of the health system) for chosen populations should be assessed. Agreed core outcome sets (CSO) should be used as endpoints in conditions where they already exist, in other cases efforts should be made to agree on such COS.

Randomised controlled trials, pragmatic trials, observational studies, large scale databases and meta-analyses may be considered for this topic. The study population should address gender balance where relevant.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Evidence base for more effective and safer interventions, and for enhanced compliance, in the elderly population, and the use of health technology assessment methodology in this target group. In particular:
  - Improvement of individual patient outcomes and health outcome predictability through tailoring of interventions
  - Improvement of guideline development for diseases and the management of comorbidities
  - Support to regulatory guidance in this population and provision of more accurate information to patients and prescribers
Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population

Specific challenge: Knowledge about the overall benefit of healthcare interventions in the paediatric population is currently limited and may result in inappropriate interventions with acute or potentially lifelong impact on health and well-being.

Increasing knowledge in the areas of intervention effectiveness and clinical research has the potential to achieve system-wide improvements in health care quality and health outcomes. Effectiveness research in children and adolescents is required which is targeted, designed, conducted, and reported in ways that include clinically important differences in the type and course of disease in children.

Scope: Proposals should focus on clinical research approaches providing a deeper understanding of effectiveness, efficacy and safety of healthcare interventions and the use of health technology assessment methods in the paediatric population.

In order to achieve this, applicants should propose a detailed programme based on clinical trials and/or real world data. The programme should address clinical, therapeutic (including pharmaco-dynamic and pharmaco-kinetic properties wherever relevant) and safety aspects of the healthcare interventions of interest, with a view to the identification and assessment of benefits and risks. Guidelines for best practice from healthcare associations and authorities must be taken into account when applicable.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Significantly decreasing treatment related risk in the paediatric population (e.g. by researching adverse drug reactions, medical device deficiencies, etc.)
- Establishing novel and/or more effective treatment schemes for healthcare interventions in the paediatric population
- Validating benefits of novel and/or frequently used health interventions in the paediatric population
Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

Advancing active and healthy ageing

PHC 19 – 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments

Specific challenge: Citizens in an ageing European population are at greater risk of cognitive impairment, frailty and social exclusion with considerable negative consequences for their independence, quality of life, that of those who care for them, and for the sustainability of health and care systems.

The challenge is to develop new breakthroughs for active and assisted living based on advanced ICT solutions.

Scope: Proposals should focus on service robotics in assisted living environments which can help an ageing population to remain active and independent for longer. Proposals should build on advances in this domain, and should combine multi-disciplinary research involving behavioural, sociological, health and other relevant disciplines. Characteristics of the solutions developed should be their modularity, cost-effectiveness, reliability, flexibility in being able to meet a range of needs and societal expectations, applicability to realistic settings, safety and acceptability to end-users. Gender and ethical issues should be paid due attention.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Evidence for the benefits of service robotics developed, based on proof of concept and involvement of relevant stakeholders
- Reduction of admissions and days spent in care institutions, and prolongation of time spent living in own home when ageing with emerging functional impairments.
- Improvement in quality of life of older persons and of their carers
- Global leadership in advanced solutions supporting active and healthy ageing

Type of action: Research and innovation actions
The conditions related to this topic are provided at the end of this call and in the General Annexes

**PHC 20 – 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment**

**Specific challenge:** Citizens in an ageing European population are at greater risk of cognitive impairment, frailty and social exclusion with considerable negative consequences for their independence, quality of life, that of those who care for them, and for the sustainability of health and care systems. The challenge is to deploy innovative and user led ICT pilot projects in support of independent living with cognitive impairments and translate promising results into scalable practice across Europe.

**Scope:** Pilots should build on common, flexible and open ICT solutions which can be adapted to specific users' needs, allowing them to live independently for longer while experiencing cognitive impairment. Pilot deployment across Europe should develop best-practice and viable business and financing models, as well as evidence for potential return on investment. Gender and ethical issues should be paid due attention.

Proposals should focus on innovation in organisational and business models for service delivery, as well as standardisation and interoperability work on required ICT platforms, services and data sources. The number of users involved should be sufficient to ensure statistical significance in impact analysis, with a minimum of 4 pilot sites in 4 countries.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Based on quantitative and qualitative output indicators and impact data, each pilot is expected to demonstrate relevant contributions to the following expected impacts:
  - Clear evidence on return of investment, both for the private sector and in terms of societal benefits from ICT based solutions for cognitive impairments of older people;
  - Best practice for viable business and financing models which are scalable across Europe;
  - Clear evidence on the improvements of efficiency of health and care systems
Clear evidence of improvements to quality of life and active ageing for involved users and carers;

Contribution to the competitiveness of the European ICT industry in the domain, through enhanced interoperability and scalable markets;

**Type of action**: Innovation actions

**The conditions related to this topic are provided at the end of this call and in the General Annexes**

**PHC 21 – 2015: Advancing active and healthy ageing with ICT: Early risk detection and intervention**

**Specific challenge**: Citizens in an ageing European population are at greater risk of cognitive impairment, frailty and social exclusion with considerable negative consequences for their quality of life, that of those who care for them, and for the sustainability of health and care systems.

The earlier detection of risks associated with ageing, using ICT approaches, can enable earlier intervention to ameliorate their negative consequences.

**Scope**: Proposals should focus on early risk detection and intervention: specifically ICT based solutions which support active and healthy ageing by enabling early detection and minimisation of risks associated with ageing, including (but not limited to) cognitive impairment, frailty, depression and falls.

Proposals should demonstrate the link between changes in behaviour and subsequent negative consequences of ageing by unobtrusive behavioural sensing, and large scale collection of data readily available in the daily living environment of older individuals.

Proposals should also design ICT based interventions countering identified risks, as well as innovative treatments and therapies based on early detection.

Proposals should build on multi-disciplinary research involving behavioural, sociological, health and other relevant disciplines, and on stakeholder engagement in order to be driven by relevant user needs to ensure end-user acceptance (including gender aspects). Full account should be taken of relevant data protection aspects.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**
Evidence for the benefits of risk detection and intervention, based on proof of concept and involvement of relevant stakeholders

Clear improvements of outcomes for individuals, care systems and wider society from new therapies and interventions based on early risk detection in comparison with current practices.

Global leadership in ICT based innovation for active and healthy ageing.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 22 – 2015: Promoting mental wellbeing in the ageing population**

**Specific challenge:** Health and care of the rapidly growing older population in Europe and elsewhere poses a number of specific challenges. Among these, the burden posed by mental and neurological conditions on older citizens has a significant impact on their working capacity, quality of life and that of their care givers, and interacts with the course and treatment of comorbidities which are frequently associated with old age.

Although some mental disorders like depression, anxiety, insomnia, dementia, personality disorders and substance use-related disorders are not limited only to older people and may have their origins in events experienced earlier in the lifespan, they are often present in clinical forms specific to older people, and may require adapted therapeutic approaches. In addition, non-age-specific mental illnesses may complicate or contribute to other, more specific age-related chronic disorders. The prevalence of these disorders is high and increasing, and difficulties in their treatment are compounded by the underrepresentation or even exclusion of older persons from many clinical trials in the field of psychiatry.

**Scope:** Proposals should include multi-disciplinary research to improve the understanding, prevention, early diagnosis, and treatment of, mental conditions and disorders of older people. This may include a dimension of research into physical, psychological, environmental and social determinants of healthy ageing.

Proposals may address the role of external or internal determinants of mental health, including e.g. behaviour, resilience, sensory deficits, chronic disease, substance use, socio-economic stressors (e.g. loneliness, poverty, violence, trauma and conflicts), or other physical and environmental stressors. Clinical trials or comparative effectiveness research should contribute to the establishment of integrated preventative or therapeutic intervention strategies to improve mental health in the older population. Preference will be given to interventions with high public health relevance, i.e. addressing particularly frequent or severe situations, with a high impact on the quality of life of the individual and/or associated with a significant socio-economic burden.
Issues of particular relevance for the target populations, such as self-medication, poly-pharmacy and compliance, and gender specificities should also be taken into account.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Improved therapeutic management of older patients affected by mental conditions and disorders.
- Maintenance of cognitive abilities of older people
- Establishment of preventative strategies favouring the mental dimension of healthy ageing.
- Reduction of the negative impact of mental disorders on comorbidities.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**Integrated, sustainable, citizen-centred care**

**PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems:**

**Specific challenge:** Public health, biomedical, social and behavioural research have provided evidence for new approaches to prevention, primary care and treatment. Their integration into health services requires cooperation across sectors and between stakeholders, and challenges the current boundaries of healthcare and established norms of operation.

EU Member States have thus far had different responses to the need for reform, presenting an opportunity to learn how best to react to preserve and promote population health, mitigate the effects of the economic crisis and avoid increases in health inequalities.

**Scope:** As action oriented research, proposals should develop new, or improve on existing, models for health systems, in order to make these systems more patient-centred, prevention oriented, efficient, resilient to crises, safe and sustainable.

The models’ applicability and adaptation to different European health systems and EU regions should be assessed, and their value, including individual and societal benefits, demonstrated.
Models may apply to different levels within the health system (micro – the patient interaction level, meso- the health care organization and community level, and macro - the policy level). They must be compared with alternatives (including existing models), capitalising on Europe's diversity. Views of relevant stakeholders such as policy makers and citizens should be taken into account in the design of and evaluation of these models. The gender dimension should be duly addressed. Capacity building and awareness raising activities for the adoption and further use of models developed should be included.

Proposals should address the related challenge of ensuring appropriate and sufficient resources (human, financial, infrastructural, equipment (or consumables) and technology) for these new models and develop adequate governance mechanisms. Proposals may include methodological work in the field of health technology assessment, health systems performance assessment, health workforce analysis as well as indicators and measures to describe and monitor the quality of life of European citizens adequately, taking into account the diverse socio-demographic groups and cultural backgrounds, and should track costs.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- On the basis of quantitative and qualitative indicators, evidence for new or improved patient-centred, prevention oriented, safe and efficient models for health care systems and services.
- Evidence to be used by policy makers and decision makers in making improvements to health and care systems, health and other policies.

Type of action: Research and innovation actions

_The conditions related to this topic are provided at the end of this call and in the General Annexes_

**PHC 24 – 2015: Piloting personalised medicine in health and care systems**

Specific challenge: Personalised medicine\(^\text{15}\) has the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities and in doing so contribute to the sustainability of health and care systems.

\(^\text{15}\) Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention
If this potential is to be realised at a larger scale it must first be demonstrated in terms of sustainable benefits, and as a new model of care organisation. Demonstration is however complicated by the diversity of European Union health systems.

**Scope:** Pilots of new models of care, based on the concept of personalised medicine should be conducted in existing health care environments and should take into account Europe's (national and regional) diversity in health system organisation.

Proposals should ensure coordination with national, regional or local authorities engaging in health sector reform, with the design of new models taking into account the views of other relevant stakeholders, including policy makers and citizens. Behavioural, ethical, legal, social implications as well as the gender dimension should be addressed.

The health, economic and social impact of the implementation of these pilots on individual patients, whole or stratified population groups, and their impact at the level of health care systems should be assessed. The organisational and resource requirements of the piloted models (data, personnel and financing) should be tracked, providing evidence on methods of implementation and benefits of reform while ensuring safety, equity and cost effectiveness. Appropriate measures for knowledge transfer and capacity building should be put in place.

The Commission considers that proposals requesting a contribution from the EU of between EUR 12 and 15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** On the basis of quantitative and qualitative indicators, evidence for a validated model of organisation of care based on the concept of personalised medicine should be produced, to be used by policy makers and decision makers in making improvements to health and care systems.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 25 – 2015: Advanced ICT systems and services for Integrated Care**

**Specific challenge:** Research on new models of care organisation demonstrates that advanced ICT systems and services may have the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities and in doing so contribute to the sustainability of health and care systems.
One challenge in re-designing health and care systems is to develop integrated care models that are more closely oriented to the needs of patients and older persons: multidisciplinary, well-coordinated, anchored in community and home care settings, and shifting from a reactive approach to proactive and patient-centred care.

Scope: Proposals should go beyond the current state of art in tele-health and tele-care systems by developing new approaches for integrated care supported by ICT systems and services. Proposals should address barriers from technological, social and organisational points of view in the following domains:

- Development of robust, privacy compliant, accurate and cost-effective systems that facilitate monitoring of patient status, patient activity and compliance with therapy;
- Fusion, analysis and interpretation of patient and care provider data, to improve decision making among formal and informal care givers and patients;
- Multi-channel and multi-actor interaction and exchange of knowledge in integrated care settings, across digital collaborative platforms;
- Development of patient-oriented services to support patient empowerment, self-care, adherence to care plans and treatment at the point of need;
- Development of new patient pathways, new training programmes for the care workforce and new organisational models to improve the coordination of care services as well as the skills and collaboration of health professionals, social carers and informal care givers;
- Personalisation of care management programmes to specific characteristics of patients' profiles, through analysis of multimodal data, risk stratification algorithms for chronic diseases and multi-morbidity conditions, predictive algorithms of patient's status, and personalisation tools for patients and;
- The creation of new knowledge for the management of co-morbidities and for addressing poly-pharmacy.

The design process of such ICT systems and services should entail participation of a wide range of users, developers and stakeholders, including medical doctors, nurses, social workers, patients as well as programmers and interaction designers. Gender and ethical issues should be paid due attention. Validation should provide proof-of-concept with both qualitative parameters and quantitative success measures.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:
• Reduced admissions and days spent in care institutions, and improvements in the daily activities and quality of life of older persons through effective use of ICT and better coordination of care processes.
• Strengthened evidence base on health outcomes, quality of life and care efficiency gains from the use of ICT in integrated care.
• Improved cooperation and secure information exchange among the actors involved in health, social and informal care services.
• Improved interaction between patients and their carers, and more active participation of patients and their relatives or other informal care givers in care processes.
• Improved usability and adaptability of ICT systems for integrated care, taking account of the complex relationship between digital technologies and their social and human context of application.
• Reinforced medical knowledge with respect to management of co-morbidities.
• Strengthened European industrial position in ICT products and services by measurable indicators such as new business areas, start-ups and protected intellectual property

**Type of action:** Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

**PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth**

**Specific challenge:** Empowering citizens to manage their own health and disease will result in more cost-effective healthcare systems by improving utilisation of healthcare, enabling the management of chronic diseases outside institutions, improving health outcomes, and by encouraging healthy citizens to remain so.

Several clinical situations would be prevented or better monitored and managed with the participation of the patient him or herself. Care sciences may complement the medical perspective without increasing the cost. This requires research into socio-economic and environmental factors, dietary impact and cultural values, behavioural and social models, attitudes and aspirations in relation to personalised health technologies, mobile and/or portable and other new tools, co-operative ICTs, new diagnostics, sensors and devices (including software) for monitoring and personalised services and interventions which promote a healthy lifestyle, wellbeing, mental health, prevention and self-care, improved citizen/healthcare professional interaction and personalised programmes for disease management. Support for knowledge infrastructures is also required, as well as the combination of predictive personalised models with personal health systems and other sources of data.
**Scope:** Proposals may focus on patients or healthy persons or both. Health management should be addressed in a holistic approach, from healthy lifestyle, dietary habits interlinked with disease management, and adherence to medical plans, placing the patient in the centre and putting increased emphasis on health education, patient empowerment, secondary prevention and self-management of individual conditions, including co-morbidities and frailty. Implementation of programs or applications for different target populations to capture gender- and age-dependent differences in health, behaviour and handling of devices should be included.

Proposals are invited which address this specific challenge by focusing on only one of the two elements below:

(i) citizen engagement in health, wellbeing and prevention of diseases.

Proposals shall enable individuals to become co-managers of their health and wellbeing (including physical and mental wellbeing, equality, health literacy, life style factors such as nutrition and smoking) with the help of ICT, tools and personalised services. The focus should be on the following elements:

- The creation of a supportive environment for healthy behaviour including support to behavioural change e.g., mathematical, dynamic modelling of behaviour with quantitative, testable models especially in real world settings and application of the sciences in designing interventions or game based physical training with motion tracking based feedback;

- Health promotion, health literacy and disease prevention;

- The development of a multi-stakeholder ecosystem (of health and care professionals, patients, nutrition - and pharmaceutical industries, public healthcare authorities, health IT, mHealth actors, health insurers and regulators, etc…) to develop a 'co-production of health' business model – an evidence based, general, alternative way of creating and augmenting personalised health, supported by information exchange and utilisation and;

- A migration path towards comprehensive solutions that could be incorporated into health care processes.

(ii) mHealth applications for disease management

Proposals should focus their research on application development for disease management with the following characteristics:

- Strong emphasis on co-designing and user needs as a key driver;

- Knowledge management systems to analyse and compile the data collected by applications on individuals’ health and activities in order for such information to be used by the persons themselves, health professionals and public health monitoring authorities;
• Guidance for patients, care-givers, families and patients' social environment on chronic disease management supported by mHealth;
• Patient adherence to and compliance with medical recommendations
• Economic aspects of encouraging secondary prevention and addressing avoidable negative health and wellbeing outcomes;
• Screening for pre-frailty states
• Public health or health promotion interventions addressed to large sectors of population through mHealth applications and;
• Co-operative ICTs to support co-operative management of health and disease among patients and eco-health systems.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: In both cases (i) and (ii)

• Improved self-management of health, disease prevention, management of diseases and/or expenditure.
• Strengthened evidence base on health outcomes, quality of life, care efficiency gains and economic benefits from the use of ICT in new care models, in compliance with data protection requirements.
• Increased confidence in decision support systems for wellbeing and disease / patient management.
• Strengthened evidence and improved knowledge about individuals' behaviour related to wellbeing, disease prevention or management facilitating the creation of new personalised behavioural health interventions.

For (i) only
• Validated programmes for health promotion and disease prevention
• Ecosystem and new business models for promotion and co-production of health

For (ii) only
• Improved service offering and business concepts and models
• Impact in several of the following facets of mHealth e.g., patient safety, contribution to or revision of (guidelines of) relevant legal frameworks, medical guidelines, harmonisation (across borders), standards, co-ordination of therapies, recognition of mHealth as a reimbursable cost, improved accessibility, liability, inter-operability, more reliable connectivity, patient empowerment, improved patient-health professional interaction, maturing personalised health systems, sustainability, usability and user-acceptance.
Improved interaction between patients, their relatives and care givers, facilitating more active participation of patients and relatives in care processes.

Improving the management of disease by reducing the number of severe episodes and complications.

Increased level of education and acceptance by patients and care givers of ICT solutions for personalised care.

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 27 – 2015: Self-management of health and disease and patient empowerment supported by ICT**

**Specific challenge:** Empowering citizens and patients to manage their own health and disease can result in more cost-effective healthcare systems by enabling the management of chronic diseases outside institutions, improving health outcomes, and by encouraging healthy citizens to remain so. Several clinical situations would be prevented or better monitored and managed with the participation of the patient him or herself. Care sciences may complement the medical perspective without increasing the cost.

This requires research into socio-economic and environmental factors and cultural values, behavioural and social models, attitudes and aspirations in relation to personalised health technologies, mobile and/or portable and other new tools, co-operative ICTs, new diagnostics, sensors and devices (including software) for monitoring and personalised services and interventions which promote a healthy lifestyle, wellbeing, mental health, prevention and self-care, improved citizen/healthcare professional interaction and personalised programmes for disease management.

Support for knowledge infrastructures is also required. Implementation of programs or applications for different target populations to capture gender- and age-dependent differences in health, behaviour and handling of devices is encouraged.

This topic is a continuation of PHC 26 – 2014) giving more and different opportunities to develop solutions and services for self-management of health and diseases.

**Scope:** Solutions should be developed and tested with the use of open innovation platforms such as large scale demonstrators for health and service innovation. Gender and ethical issues should be duly considered. Proposals should involve health procurers and support them in their efforts to lower costs, and reduce difficulties associated with limited numbers of health professionals by utilising the capacity and potential of the patient as a co-producer of health. Proposals should use pre-commercial procurement to maximise the engagement of innovation
in healthcare organisations following the community building and road-mapping activity in the seventh framework programme call 10 CSA on innovation in health procurement\(^\text{16}\).

Proposals should aim to empower patients to manage their pre-existing conditions. Health management will be addressed holistically, including healthy lifestyle interlinked with disease management, placing the patient in the centre and putting increased emphasis on health education, secondary prevention and self-management of individual conditions, including co-morbidities.

Proposals should address all of the following elements a) personalised guidance to patients based on their profiles and the use of wearable/portable devices and improved individual/healthcare-professional interaction, b) engagement of patients as active members in managing their diseases, in particular addressing chronic diseases, co-morbidities, treatment adherence, rehabilitation, self-diagnostics and self-care and c) decision support systems interoperable and/or maintaining integrity with electronic health records.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Improving the participation of the patient in the care process.
- Improving the management of a disease by reducing the number of severe episodes and complications.
- Increasing the level of education and adherence of individuals, patients and care givers related to application of ICT for personalised care.
- Improved interaction between patients, their relatives, providers of health-, social-, and informal care givers.
- Strengthened evidence base on health outcomes, quality of life, care efficiency gains and economic benefits from the use of ICT in new care models.
- Reinforced medical knowledge with respect to efficient management of comorbidities.
- Increased confidence in decision support systems for disease/patient management.

\(^{16}\) [http://ec.europa.eu/research/participants/portal/page/call_SEVENTH FRAMEWORK PROGRAMME;eSeventh Framework Programme_SESSION_ID=QJb3S2ZR4e5R8YGRdcXg6sMvRGlhp5MnfdJ6hwS2s2Zdph80JKMYL!1216744746?callIdentifier=SEVENTH FRAMEWORK PROGRAMME-ICT-2013-10&specificProgram=COOPERATION#wlp_call_SEVENTH FRAMEWORK PROGRAMME]
Involvement of health care providers/authorities with increased commitment in the deployment of innovative services empowering the patient.

**Type of action:** Pre-commercial procurement co-fund actions.

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**PHC 28 – 2015: Self-management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself**

**Specific challenge:** Several clinical situations would be prevented or better monitored and managed with the participation of the patient him or herself. In order to promote the self-management, predictive personalised models can be combined with personal health systems and other sources of data (clinical, biological, therapeutic, behavioural, environmental or occupational exposure, lifestyle and diet etc.) and used by the patient him or herself, in order to raise individual awareness and empower the patient to participate in the management of his or her health, with application in lifestyle, wellbeing and prevention, in monitoring of the disease etc. This will improve the quality of life of patients and the self-management of disease and lifestyle.

**Scope:** Proposals should focus on predictive systems based on computer modelling and will develop decision support systems (DSS) that will be used by the individual. The DSS should include the collection of various data (patient, clinical, biological, therapeutic, behavioural, environmental or occupational exposure, physical training and performance, lifestyle and diet, environmental data, social data etc.). Connected existing predictive models should process these data in real-time to predict how the health of the patient will evolve in the near future and such predictions, accompanied with all relevant information regarding their uncertainties and limits should be used by the patient / citizen him or herself for self-management of health and wellbeing. These DSS may also help to improve interactions between individuals / health professionals and co-decision making in healthcare. Proposals may also include combination with monitoring personal health systems and other technologies and sources of data, as e.g., tools for data collection on external factors potentially linked to disease. Gender and ethical issues should be duly considered.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Improving the participation of the patient in the care process.
- Improving the management of a disease by reducing the number of severe episodes and complications.
• Increasing the importance of the prevention sector in healthcare using predictive modelling.

• Boosting the development of personal devices used for self-management of health.

• Improving individual self-control of health and of disease prevention

*Type of action: Research and innovation actions*

The conditions related to this topic are provided at the end of this call and in the General Annexes

**PHC 29 – 2015: Public procurement of innovative eHealth services**

**Specific challenge:** The sustainability of pilot and demonstration solutions and services is broadly perceived as one of the biggest challenges in streamlining healthcare delivery processes and in improving cost efficiency while maintaining or improving patient safety. The pace of development has been slow and penetration of ICT still has high growth potential in healthcare compared to other public or private sectors.

This activity facilitates public purchasing of innovative solutions in healthcare which have not yet been deployed on a large scale.

**Scope:** The proposals should improve sustainable deployment of new or improved services by healthcare service procurers in line with the eHealth Action Plan. Examples of target outcomes for healthcare delivery may include addressing early hospital discharge, delivery of healthcare in remote, sparsely populated and difficult to access regions, eHealth services for mobile EU patients, and pre/post operation care outside the hospital environment.

The scope of the PPI pilot(s) is to specify, purchase and deploy ICT based solutions which can deliver sustainable, new or improved healthcare services and improve the ecosystem in which procurement approaches for innovative healthcare solutions are successfully applied.

Proposals should be driven by clearly identified procurement needs of healthcare organisations and provide for appropriate public engagement:

• Solutions should be based on a complete set of common specifications for technology and end to end services;

• The implementation phase should have the ambition to reach a large scale across multiple regions of Europe;

• Proposals must engage public and/or private procurers from each country participating (at national, regional or local level) that have responsibilities and budget control in the relevant area of care or supply of services;

Wherever possible the work should build on and contribute to relevant standards to ensure interoperability and take into account best practices and relevant standardisation efforts as well as provide appropriate safeguards against relevant ethical and privacy issues;

The work shall include a non-confidential, comprehensive socio-economic evidence base for ICT investments in the field (including e.g. cost-benefit analysis, assessment of impacts, return on investments, medical evidence, patient safety gain and user satisfaction) to facilitate the development of sustainable business models and;

Good practice shall be made available for replication in other regions, for example detailed plans for larger-scale sustainable uptake as well as reference material including guidelines, manuals and educational materials.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- As applicable, contribution to regulatory and legal process development addressing possible barriers to procurement of innovative solutions in healthcare.
- Growing awareness and successful use of public procurement by the procurers to boost innovation in the application of ICT in the sector concerned.
- Support to interoperability and defragmentation of the market.
- Sustainable implementation of services and creation of economic conditions that support long-term development.
- More forward-looking, concerted, public sector approach to eHealth.
- Reduced fragmentation of public sector demand across a number of EU Member - or Associated States by enabling public purchasers to collectively implement PPI strategies, which due to their nature are better addressed jointly, or which they would not have been able to tackle independently.
- Increased opportunities for wide market uptake and economies of scale for the supply side for ICT based solutions and services by forming critical mass on the public demand side.

Type of action: Public procurement of innovative solutions co-fund actions.

The conditions related to this topic are provided at the end of this call and in the General Annexes
Improving health information, data exploitation and providing an evidence base for health policies and regulation

PHC 30 – 2015: Digital representation of health data to improve disease diagnosis and treatment

Specific challenge: Digital personalised models, tools and standards with application for some specific clinical targets are currently available. There is however a need for greater integration of patient information, for example of multi-scale and multi-level physiological models with current and historical patient specific data and population specific data, to generate new clinical information for patient management. Any such integrative digital representation (Digital Patient) must also allow meaningful knowledge extraction and decision support.

Scope: Proposals should focus on new decision support systems (DSS) based on a complex integration of heterogeneous data sources and subject-specific computer models. This should enable an integrated data analysis, and should present a highly visual data representation, using user-friendly interactive exploratory interfaces in order to assure usability and acceptability.

Proposals should enable the use of DSS by healthcare professionals for personalised prediction and decision in prevention, diagnosis or treatment and should take into account data protection and ethical considerations, as well as those pertaining to the inherent uncertainties and limits of prediction. The models should be already available, multi-level and multi-scale and will be integrated with the individual and population data relevant for the targeted clinical situations, e.g. the required molecular and cellular data, including genomics and epi-genomics, *in vivo* and *in vitro* imaging data, or data on administration of therapeutics and on nutrition/exposure to environmental factors and will be linked when relevant with computer models of personalised physiology, functional disorders and other diseases. The proposed systems should take advantage of the personal medical data accumulated over time.

Proposals should include the standardisation of data formats. The integration of data coming from other new technologies for e.g. key-enabling technologies should be considered. Gender and ethical issues should be duly considered.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Better coherent use of health data available for a subject in conjunction with the existing medical knowledge in clinical decision making
- Design of predictive and therapeutic interventions
- Better management of complex clinical situations.

PART 8 - Page 45 of 103
• Enabling use of the same information by different medical services and the other relevant healthcare professionals.

• Better control and inter-service coordination in the management of the patient health.

• Providing a consistent view of a patient's care needs.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 31 – 2014: Foresight for health policy development and regulation

Specific challenge: The complex interactions between multiple determinants of health and wellbeing are not well understood. These include but are not limited to air quality, climate change, traffic and congestion, ambient noise, built environment, urban sprawl, sustainable food systems, waste, lifestyle, behaviour, occupation, demographic change, cultural characteristics, socio-economic factors, globalisation of exchanges of goods and people and so on.

Adding to the complexity, currently used measures and indicators of health status and quality of life are inadequate to capture the effect of these interactions and there is a lack of comparable health related data as produced by different health information systems. Furthermore, the co-existence of a multitude of analytical frameworks, often not multi-factorial in nature, limits the comprehensiveness of the assessment.

Foresight is a powerful tool in providing a systematic and structured approach for understanding stress factors and facilitators affecting health and wellbeing, analysing the range of possible outcomes and for helping to define policy options

Scope: Proposals should identify key driving forces- (external and internal to the health systems) likely to influence health and wellbeing in Europe and beyond in the future. Proposals should contribute to the understanding of the inter-relationships between these factors; analyse their economic and social impact and suggest alternative policy options to respond to the challenges they pose. Proposals should present a comprehensive, structured and participatory framework of analysis, integrating and quantifying key factors impacting health, health inequalities and demand for health services taking Europe's diversity into account. Use of Copernicus\(^{18}\) data, products and information may be considered where relevant.

\(^{18}\) www.copernicus.eu
Use should be made of current techniques for foresight such as horizon scanning, trend monitoring, and analysis based on epidemiological surveillance (of health and health determinants), weak signal analysis, expert opinion (to create collective intelligence), scenario development, back-casting and wildcards (to help define alternative futures).

Proposals should include quantitative analysis, such as environment, health, economic and other modelling and sensitivity analysis to measure variation in impact of different factors. Proposals should include the identification and validation of relevant measures & indicators and the development of (common) standards. Proposals should capitalise on existing good practice in Europe as well as international level experiences.

The usefulness of current health data and statistics for these modelling exercises should be assessed and suggestions for improvement made. Proposals should also include networking between centres with existing expertise in (health) foresight, both public and private, and partnerships with centres aspiring to develop this expertise.

If more than one proposal is successful, proposals should collaborate and this should be indicated in the proposal.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Through the use of a validated analytical framework with a robust set of standardised indicators, the ability to model and track the impact of various factors (internal and external to the health systems) on population health should be improved.

- A basis for policy dialogue, facilitating timely decision making in the EU MS and beyond with regards to health sector reform and guide investments in health care to improve population health.

- Guidance for future health research

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 32 – 2014: Advancing bioinformatics to meet biomedical and clinical needs

Specific challenge: Recent technological advances in molecular biology, biomedical sciences and systems biology have enabled a greatly increased rate of data generation and the production of many different types of data. Furthermore, these new technologies are gradually
becoming much less expensive and more accessible to individual laboratories and clinics. The rate of data generation at a local level is therefore set to increase dramatically.

Currently available bioinformatics tools are however insufficient to maximise the use of these new, diverse and complex data. Deficiencies exist in data collection, storage, organisation, integration, analysis and exploitation is therefore not optimal. Network bioinformatics requires support in Europe in order to maintain scientific competitiveness.

**Scope:** Proposals should ensure that bioinformatics capabilities are not only made adequate for the current data challenge but are also able to meet future biomedical and clinical needs. Proposals should focus on the development of new mathematical, statistical and computational methods, to address specific bottlenecks in bioinformatics that hold back better understanding, integration and use of biomedical and clinical research data. The needs include, but are not limited to: better data capture, organisation and storage; improved data analysis and processing methodologies, and interoperability; new approaches for data integration (e.g. different types and sources, integration of the time component); new approaches to data standardisation, including development of both preclinical and clinical standard operating procedures, ensuring data consistency and sharing while also complying with data protection requirements; improving accessibility and user-friendliness of biomedical and clinical research data. Close links between developers and envisaged end-users of the new methods must be ensured from the start of all successful proposals, as must widespread dissemination of the new methods. Commercial development should be a goal where appropriate.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**
- Accelerate the translation of the results into clinical research
- Widespread dissemination of the new bioinformatics methods to maximise the accessibility and utility of biomedical data in research and medicine
- Increased commercial products in bioinformatics (e.g. data services).
- Increased research & innovation opportunities in this SME-intensive field
- Building on European excellence to make the EU a location of choice for advanced bioinformatics research

**Type of action:** Research and innovation actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*
PHC 33 – 2015: New approaches to improve predictive human safety testing

Specific challenge: Current approaches assessing the safety of chemical substances in humans are expensive and time consuming, and may be of limited relevance as a predictor of adverse effects. Better approaches are needed both to improve the efficiency of predictive toxicological testing to address key areas of concern for human health and to meet regulatory requirements (e.g. EU legislations on REACH, cosmetics, biocides). Safety testing is of worldwide concern and therefore international cooperation may be an important element in addressing the challenge.

Scope: Proposals should capitalise on advances in all relevant fields of science to understand complex biological pathways of toxicological relevance and to identify early markers predictive of toxicological effects in humans with the objectives of developing and validating routine, non-animal approaches for toxicity testing of chemical substances (excluding radio-chemicals). The research may include the development of methodologies for confirmatory testing of mechanistic hypotheses to improve understanding of toxicity mechanisms.

Proposals should involve, amongst others, research communities, SMEs, industry and regulatory agencies as appropriate. Proposals should demonstrate efficient mechanisms for the co-ordination of activities and exchange of information, and should include a timeline for delivery of test methods.

In line with the Union’s strategy for international cooperation in research and innovation, cooperation is encouraged with similar initiatives in the USA and elsewhere, and would be highly beneficial from scientific and economic standpoints.

Proposals could consider the involvement of the European Commission Joint Research Centre (JRC) as an added value in order to provide an effective interface between the research activities and regulatory aspects and/or to translate the research results into validated test methods and strategies fit for regulatory purpose. In that respect, the JRC will collaborate with any successful proposal.

Applicants are encouraged to seek during the life-time of the project additional support from various sectors in order to facilitate translational aspects.

The Commission considers that proposals requesting a contribution from the EU of between EUR 10 and 30 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

---

19 COM(2012)497
Expected impact:

- More effective, faster, cheaper toxicological testing to better predict human risk and meet regulatory needs.
- Improved toxicological knowledge to encourage ‘read across’ between chemical substances for use in different research and regulatory domains.
- Commercial exploitation of the developed toxicological testing methods and assessment approaches, products and services.
- Advancement of international co-operation in the field of predictive toxicology and human safety testing.
- Reduced use of laboratory animals in safety testing.

Form of funding: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

PHC 34 – 2014: eHealth interoperability

Specific Challenge: There are a number of challenges to effective eHealth service deployment in Europe, each of which is to be addressed by an individual Co-ordination and Support Action as below.

(i) There is little stakeholder consensus on a common reference information model for eHealth deployment in Europe, and it seems unlikely that international consensus can be reached for common (clinical) reference standards in a reasonable timeframe and budget. It is therefore reasonable to ask whether competing / overlapping standards can co-exist in a common eHealth European interoperability framework; this is of relevance to the MoU on eHealth between the EC and the US department of Health and Human services.

(ii) The Directive on patients' rights in cross-border healthcare (Directive 2011/24/EU) pursues the objective to enhance safety and continuity of cross-border treatment through interoperable access to patients' summary data and interoperable ePrescriptions. The challenge in ePrescription is how medicines can be communicated in the cross border setting. There is neither a common data model nor a common vocabulary for medicinal or pharmaceutical products throughout Europe.

(iii) The clinical domain is probably among the most complex from a semantic point of view. Vocabularies, terminologies, classification and coding systems, and ontologies have been developed by different stakeholders to address different needs in different subdomains. The semantic health report had already demonstrated the central role that SNOMED CT could play...

http://www.ihtsdo.org/snomed-ct

20
play as a core terminology to solve semantic interoperability issues, provided that "evidence-based results of SNOMED CT’s fitness for purpose are assessed". The epSOS pilot project has retained SNOMED CT as one of the constituents of its master value sets catalogue which ensures semantic interoperability across the borders in the frame of the pilot. More recently, the eHealth Network called on the Commission to play a more active role in assessing the value of SNOMED CT for eHealth deployments in Europe. A detailed analysis on the advantages and disadvantages, as well as the impact of using SNOMED CT as the core terminology at the EU level is needed.

(iv) The Connecting Europe Facility will provide the funding and the governance framework to deploy cross border eHealth Services, among other digital services, until 2020. The intention is to migrate progressively the Connecting Europe facility from a publicly funded initiative to a self-financed operation. There is a need to identify the right business model and plan which would identify sustainable sources of revenue and all the costs which the operations of such services would generate. Gathering evidence that interoperability contributes to lowering the cost of health systems is an important element for decision makers when they have to envisage eHealth investments.

Scope: (i) The proposal should at minimum build on existing CEN, ISO, and HL7 standards. The need for a formal standardization activity in the area should be demonstrated, as well as a realistic roadmap with concrete deliverables. Alternative scenarios should be envisaged. Proposals should build on existing initiatives and EU projects in the area. Proposals should ensure sufficient involvement of stakeholders (including at least Member States, Industry and international standards development organisations (SDOs)), consensus building and endorsement of the work carried out and of the submitted deliverables. Contribution to the EU eHealth Interoperability Framework should be demonstrated. The successful proposal should support large scale deployments of eHealth services (including cross border) in Europe and contribute to the implementation of the EU-US MoU and roadmap.

(ii) Proposals should investigate the possibility of combining existing or developing a new European or international standard which address the following issues:

- Unambiguous definition and description of medicinal and pharmaceutical products, including unique identification.
- Handling of substitution

Proposals should be submitted by a consortium composed of relevant international standards development organisations, member states' public authorities and fora and consortia which have a demonstrated expertise to perform the work.

Proposals should build on existing standard vocabularies, terminologies and ontologies and demonstrate a likely contribution to the adoption of existing, or the development of new international standards.
(iii) Proposals should investigate the use of SNOMED CT as a core terminology to solve semantic interoperability issues for cross border but also national and regional eHealth deployments in the EU. Proposals should cover aspects such as costs (license or membership, but also operational, translations, mapping to local terminologies, maintenance, training,...), fitness to clinical requirements, legal, technical and operational, benefits, governance, impact on the different stakeholders including patients and healthcare providers, for the cross border as well as for the national and regional scenarios. Proposals should compare the SNOMED scenario with at least two scenarios: a) do nothing at the EU level and b) define a semantic interoperability framework without SNOMED CT. Proposals should assess whether SNOMED CT satisfies the criteria listed in the annex II of the EU standardization regulation. Proposals should take into account advice and guidelines from the eHealth Network but also developments related to the EU-US roadmap.

Proposals for section (iii) should have a duration of no longer than one year.

(iv) The proposal should build on existing work done by projects such as epSOS\textsuperscript{21} and SemanticHealthNet\textsuperscript{22} which will have developed key building blocks which will help to address the challenge. The epSOS pilot project has been piloting two basic use cases (ePrescription and Patient Summary) and successful proposals should identify and agree on a roadmap of use cases that should be deployed on large scale in the future after the epSOS use cases. Proposals should demonstrate the value proposition of healthcare providers with regard to interoperability and assess sustainable incitement schemes that would encourage healthcare providers to encode health data and provide it in an interoperable way and to invest in interoperable eHealth systems.

Proposals should gather a large multidisciplinary group of stakeholders from the Member States, Regions, SDO, sectoral fora and consortia, industry, health insurance companies, key interoperability experts, patients associations, health care providers associations, and any other stakeholders which will be deemed necessary. Proposals should deliver a full business plan going beyond 2020 including all revenue streams and cost items.

The Commission considers that proposals requesting a contribution from the EU of up to EUR 1 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

\textbf{Expected impact:}

(i) Convergence in the use of eHealth Standards in Europe and in the world. Contribution to the eHealth Interoperability Framework and to large scale deployment of eHealth Services (including cross border) in Europe. In line with the Union’s strategy for international

\begin{footnotesize}
\begin{enumerate}
\item \url{http://www.epsos.eu/}
\item \url{http://www.semantichealthnet.eu/}
\end{enumerate}
\end{footnotesize}
cooperation in research and innovation\textsuperscript{23}, proposals will contribute to the implementation of the EU-US roadmap

(ii) Practical solutions to solve the specific challenge and enable large scale deployments of cross border ePrescription services in the EU. Contribution to the EU-US roadmap and MoU.

(iii) Contribute to better semantic interoperability of eHealth services in Europe, to building a European eHealth Interoperability Framework and to prepare the deployments of eHealth Services in the frame of the Connecting Europe Facility.

(iv) Contribution to the planning and road-mapping of the CEF for that which concerns the deployment of cross border eHealth services. Contribution to help the EU Member States and the eHealth Network to prioritise use cases to be deployed at national level and to better plan their own national deployments.

Type of action: Coordination and support actions

\textit{The conditions related to this topic are provided at the end of this call and in the General Annexes}

\textsuperscript{23} COM(2012)497
**CONDITIONS FOR THIS CALL**

**Opening dates**\(^{24}\):

- 11/12/2013 for 2014 topics
- 03/03/2014 for 2014 topics of PHC 12 - 2014-2015
- 30/07/2014 for 2015 topics
- 18/12/2014 for 2015 topics of PHC 12 - 2014-2015

**Deadline(s)**\(^{25}\):

**For 2014 topics:**
- 11th March 2014 (stage one of two stage call),
- 15\(^{th}\) April 2014 (single stage call),
- 19\(^{th}\) August 2014 (stage two of two stage call),
- PHC 12 – 2014/2015 (as below).

**For 2015 topics:**
- 14 October 2014 (stage one of two stage call),
- as below (single stage call),
- 21 April 2015 (stage two of two stage call),
- PHC 12 – 2014/2015 (as below).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1 – 11(^{th}) March 2014 at 17.00.00 Brussels time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Single stage – 15(^{th}) April 2014 at 17.00.00 Brussels time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 1</td>
<td>Phase 2</td>
</tr>
<tr>
<td>18/06/2014</td>
<td>24/09/2014</td>
<td>09/10/2014</td>
<td>17/12/2014</td>
<td>18/03/2015</td>
<td>18/03/2015</td>
<td>17/06/2015</td>
<td>17/06/2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{24}\) The Director-General responsible may decide to open the call up to one month prior to or after the envisaged date of opening.

\(^{25}\) The Director-General responsible may delay this deadline by up to two months.
### Indicative budget:
EUR 549.30 million from the 2014 budget\(^{27}\), EUR 543.50 million from the 2015 budget\(^{28}\)

<table>
<thead>
<tr>
<th>PHC 1 - 2014</th>
<th>54.00</th>
<th>Two stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHC 2 - 2015</td>
<td>36.00</td>
<td>Two stage</td>
</tr>
<tr>
<td>PHC 3 - 2015</td>
<td>30.00</td>
<td>Two stage</td>
</tr>
<tr>
<td>PHC 4 - 2015</td>
<td>18.00</td>
<td>Two stage</td>
</tr>
</tbody>
</table>

---

\(^{26}\) The Director-General responsible may delay this date by up to two months.

\(^{27}\) Of which EUR 5.00 million from the societal challenge ‘Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bio-economy’.

\(^{28}\) The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.
### PHC 5 - 2014
- **2014 EUR million**: 24.00
- **2015 EUR million**: Two stage

### PHC 6 - 2014
- **2014 EUR million**: 15.00
- **2015 EUR million**: Two stage

### PHC 7 - 2014
- **2014 EUR million**: 15.00 (with an additional 5.00 million from SC2)
- **2015 EUR million**: Single stage and hearing

### PHC 8 - 2014
- **2014 EUR million**: 25.00
- **2015 EUR million**: Single stage and hearing

### PHC 9 – 2015
- **2014 EUR million**: 21.00
- **2015 EUR million**: Single stage and hearing

### PHC 10 - 2014
- **2014 EUR million**: 48.00
- **2015 EUR million**: Two stage

### PHC 11 - 2015
- **2014 EUR million**: 49.00
- **2015 EUR million**: Two stage

### PHC 12 – 2014/2015
- **2014 EUR million**: 66.10
  - Out of which 6.61 for phase 1
  - 58.17 for phase 2
  - 1.32 for mentoring and coaching support and phase 3
- **2015 EUR million**: 45.00
  - Out of which 4.50 for phase 1
  - 39.60 for phase 2
  - 0.90 for mentoring and coaching support and phase 3
- **SME instrument**: Single stage for both phase 1 and phase 2.
The budget available for phase 1 and phase 2 will be divided equally between each cut-off date.

### PHC 13 - 2014
- **2014 EUR million**: 60.00
- **2015 EUR million**: Two stage

### PHC 14 - 2015
- **2014 EUR million**: 62.00
- **2015 EUR million**: Two stage

### PHC 15 – 2014/2015
- **2014 EUR million**: 36.00
- **2015 EUR million**: 37.00
  - 2014 – one stage, one deadline
  - 2015 – one stage, one deadline

### PHC 16 – 2015
- **2014 EUR million**: 36.00
- **2015 EUR million**: Two stage

### PHC 17 – 2014
- **2014 EUR million**: 48.00
- **2015 EUR million**: Two stage

### PHC 18 – 2015
- **2014 EUR million**: 28.00
- **2015 EUR million**: Two stage
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PHC 20 – 2014</td>
<td>10.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 21 – 2015</td>
<td>20.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 22 – 2015</td>
<td>17.00</td>
<td>Two stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 23 – 2014</td>
<td>30.00</td>
<td>Two stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 24 - 2015</td>
<td>30.00</td>
<td>Two stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 25 - 2015</td>
<td>20.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 26 - 2014</td>
<td>59.60</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 27 - 2015</td>
<td>15.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 28 - 2015</td>
<td>19.50</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 29 - 2015</td>
<td>10.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 30 - 2015</td>
<td>20.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 31 - 2014</td>
<td>6.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 32 – 2014</td>
<td>24.00</td>
<td>Two stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 33 – 2015</td>
<td>30.00</td>
<td>Single stage and hearing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 34 - 2014</td>
<td>4.00</td>
<td>Single stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTALS</td>
<td>549.30</td>
<td>543.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Eligibility and admissibility conditions: The conditions are described in parts B and C of the General Annexes to the work programme, with the following exceptions:

29 In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.

30 Beneficiaries will be allowed to charge the cost of clinical trials on the basis of unit costs established in line with the methodology set up in the COMMISSION DECISION (C(2014) 1393 final) of 07.03.2014 authorising the use of reimbursement on the basis of unit costs for actions requiring the conduct of clinical
A proposal for phase 2 shall include a first commercialisation plan.

Clinical trials shall only be supported in cases where "orphan designation" has been given. The orphan medicinal product must have been granted the EU orphan designation\(^{31}\) at the latest on the date of the call closure (of stage 2).

Evaluation criteria, scoring and threshold: The criteria, scoring and threshold are described in part H of the General Annexes to the work programme, with the following exceptions:

| PHC 12 – 2014/2015 | Proposals will be evaluated individually when they arrive. They will be ranked after the respective cut-off dates. If a proposal fails to achieve the threshold for a criterion, the evaluation of the proposal will be stopped. For phase 1 the threshold for individual criteria will be 4. The overall threshold, applying to the sum of the three individual scores, will be 13. For phase 2 the threshold for the criterion Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12. The final consensus score of a proposal will be the median of the individual scores of the individual evaluators; and the consensus report will comprise a collation of the individual reports, or extracts from them. Where appropriate, a Panel Review will be organised remotely. Applicants can provide during the electronic proposal submission up to three names of persons that should not act as an evaluator in the evaluation of their proposal for potential competitive reasons\(^{32}\). |
| PHC 1 – 2014, PHC 5 – 2014, PHC 6 – 2014, PHC 10 – 2014, PHC 13 – 2014, | The thresholds for each criterion at stage 1 (of a two stage process) will be 4 and 4. The cumulative threshold will be 8. The thresholds for each criterion at stage 2 (of a two stage process) will be 4, 4 and 3. The cumulative threshold will be 12. If a proposal fails to achieve the threshold for a criterion at any stage, the studies under ‘Societal Challenge 1: Health, Demographic Change and Wellbeing’ of the Horizon 2020 Framework Programme. |


\(^{32}\) If any of the persons identified is an independent expert participating in the evaluation of the proposals for the call in question, they may be excluded from the evaluation of the proposal concerned, as long as it remains possible to have the proposal evaluated.

Evaluation of the proposal will be stopped.

The median of individual evaluator scores may be used at stage 1 to determine the consensus score and when appropriate, the resulting consensus report may comprise elements of these individual reports, or standard phrases representative thereof.

The page limit for stage 1 proposals is 7 pages (including the title page).


The thresholds for each criterion at stage 1 (of a two stage process) will be 4 and 4. The cumulative threshold will be 8.5.

The thresholds for each criterion at stage 2 (of a two stage process) will be 4, 4 and 3. The cumulative threshold will be 12.

If a proposal fails to achieve the threshold for a criterion at Stage 2, the evaluation of the proposal will be stopped.

The median of individual evaluator scores may be used at stage 1 to determine the consensus score and when appropriate, the resulting consensus report may comprise elements of these individual reports, or standard phrases representative thereof.

The page limit for stage 1 proposals is 7 pages (including the title page).


The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.

If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.


The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.

**Evaluation procedure:** The procedure for setting a priority order for proposals with the same score is given in part H of the General Annexes.

The full evaluation procedure is described in the relevant guide\(^3\) published on the Participant Portal.

- Indicative timetable for evaluation and grant agreement:

<table>
<thead>
<tr>
<th></th>
<th>Information on the outcome of the evaluation (single stage)</th>
<th>Information on the outcome of the evaluation (second stage)</th>
<th>Indicative date for the signing of grant agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHC 1 - 2014</td>
<td></td>
<td>Maximum 5 months from the final date for submission to the second stage.</td>
<td>Maximum 3 months from the date of informing applicants.</td>
</tr>
<tr>
<td>PHC 5 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 6 – 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 10 – 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 13 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 17 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 23 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 32 – 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 7 - 2014</td>
<td>Maximum 5 months from the final date for submission.</td>
<td>N/A</td>
<td>Maximum 3 months from the date of informing applicants.</td>
</tr>
<tr>
<td>PHC 8 - 2014</td>
<td>For the evaluation of topics PHC7 – 2014 and PHC8 – 2014, the Commission will organise hearings at stage 1 with applicants as part of the panel deliberations for all proposals above threshold.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 15 – 2014/2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 19 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 20 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 26 – 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 31 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC 34 - 2014</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHC12 – 2014/2015</td>
<td>Two months after the corresponding cut-off date set out above for phase 1 and four months after the</td>
<td>One month from the date of informing applicants in phase 1 and two months from the date of informing</td>
<td></td>
</tr>
</tbody>
</table>
### Information on the outcome of the evaluation

**PHC 2 - 2015**
**PHC 3 - 2015**
**PHC 4 - 2015**
**PHC 11 – 2015**
**PHC 14 - 2015**
**PHC 16 - 2015**
**PHC 18 – 2015**
**PHC 22 – 2015**
**PHC 24 – 2015**

<table>
<thead>
<tr>
<th>Information on the outcome of the evaluation (first stage)</th>
<th>Information on the outcome of the evaluation (second stage)</th>
<th>Indicative date for the signing of grant agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>corresponding cut-off date set out for phase 2.</td>
<td>Maximum 5 months from the final date for submission to the second stage.</td>
<td>Maximum 3 months from the date of informing applicants.</td>
</tr>
</tbody>
</table>

### Indicative date for the signing of grant agreements

**PHC 9 - 2015**
**PHC 15 – 2015**
**PHC 21 - 2015**
**PHC 25 - 2015**
**PHC 27 – 2015**
**PHC 28 - 2015**
**PHC 29 – 2015**
**PHC 30 – 2015**
**PHC 33 - 2015**

<table>
<thead>
<tr>
<th>Indicative date for the signing of grant agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum 5 months from the final date for submission.</td>
</tr>
</tbody>
</table>

For the evaluation of topics PHC9 – 2015 and PHC33 – 2015, the Commission will organise hearings at stage 1 with applicants as part of the panel deliberations for all proposals above threshold.
Consortium agreements: In line with the Rules for Participation and the Model Grant Agreement, participants in Research and Innovation actions or in Innovation actions are required to conclude a consortium agreement prior to grant agreement. Likewise and for topic PHC12, when two or more SME submit a proposal, they are required to conclude a consortium agreement prior to grant agreement.
Co-ordination activities

Proposals are invited against the following topics:

**HCO 1 – 2014: Support for the European Innovation Partnership on Active and Healthy Ageing**

**Specific Challenge:** The strategic implementation plan (SIP) of the European innovation partnership on active and healthy ageing (EIP-AHA) has identified a number of priority action areas. In a subset of these, stakeholder action groups have developed action plans for implementing innovative services for the ageing population. Another subset of priority action areas addresses domains whose readiness towards implementation is maturing and may soon give rise to additional action plans.

The EIP-AHA has invited, among others, the European Commission to establish favourable framework conditions to implement the actions outlined in the SIP. The European Commission, in its Communication "Taking forward the Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing", committed to take account of relevant priorities of the SIP, together with input from other stakeholders, for future research and innovation work programmes and instruments.

Support is therefore required in facilitating: the execution of action plans, the establishment of favourable framework conditions for the deployment of the intended innovative services, and the future development of further action plans and priority areas.

**Scope:** Proposals should provide coordinated support to the activities of the EIP-AHA as follows:

Support the existing action groups in implementing their action plans. The support may relate for example to coordination of action group activities, communication among partners and dissemination of results;

Support the development of new action plans coming from more priority action areas identified in the strategic implementation plan of the EIP-AHA, and subsequently, support the newly formed action groups in the same way as described above;

In collaboration with relevant stakeholders, including those from civil society, identify any new areas that can be regarded as future priority action areas, and develop a roadmap of research priorities, which are needed in the context of the existing and future priority action areas;

Work together with the European Commission, with relevant legislative and standardisation initiatives and with national, regional and local authorities in developing recommendations for
more favourable regulatory and standardisation conditions, innovative procurement and incentive mechanisms.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

Proposals should present quantitative or qualitative indicators to quantify the potential impact of the following.

• Enhanced communication among EIP-AHA stakeholders, enhanced coordination of activities in the Action Groups of EIP-AHA and enhanced communication of their results.

• Identification of priority areas for Research and Innovation actions in the domain of Active and Healthy Ageing.

• Accelerated progress in the establishment of favourable framework conditions to implement the actions outlined in the Action Plans of the EIP-AHA.

Type of action: Coordination and support actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

HCO 2 – 2014: Joint Programming: Coordination Action for the Joint Programming Initiative (JPI) "More Years, Better Lives - the Challenges and Opportunities of Demographic Change"

Specific challenge: Following the implementation of the actions foreseen by the Commission’s Communication on Joint Programming to tackle Europe’s major societal challenges, the Competitiveness Council has welcomed the progress made by EU Member States in Joint Programming Initiatives (JPIs) launched so far. Several Council Conclusions on Joint Programming34 invite the Commission to support JPIs via Coordination and Support Actions.

The JPI "More Years, Better Lives - the Challenges and Opportunities of Demographic Change" enhances coordination and collaboration between national research programmes

34 Council Conclusions of 12 October 2010, of 26 November 2010 and of 8 December 2011
related to demographic change. It enables Member States to pursue common visions and a strategic research agenda on demographic change.

Proposals should provide coordination and support for the implementation of the joint programming pursued by national governments.

**Scope:** Proposals should ensure the coordination of exchange on national programmes on demographic change as well as facilitate the effective governance of the JPI. Proposals should also monitor national research activities in the area and provide support for the implementation of the Strategic Research Agenda of the JPI MYBL\(^{35}\) in particular through;

- Coordination and organisation of potential joint calls;
- Alignment of national research programmes and activities to the JPI’s Strategic Research Agenda;
- Integration and enhanced accessibility of national data related to active and healthy ageing, demographics, and statistics, to support evidence-based policy making and effective cross-policy actions; common usage of databases and infrastructures where appropriate;
- Investigate novel forms of implementation of SRA.

Proposals should provide for dissemination and awareness actions, liaison with relevant EU level initiatives, collaboration with international initiatives and third countries as well as supporting the development and dissemination of policy guidelines based on the JPI’s outcomes.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Effective governance and support to the implementation of the JPI MYBL
- A stronger international dimension of the JPI
- Better coordination of research programmes in demographic change and dissemination of policy guidelines based on the JPI’s outcome
- Alignment of national research programmes and activities with the JPI’s Strategic Research Agenda and coordination with Horizon 2020 objectives

\(^{35}\) Methods of collaboration shall follow the “Voluntary guidelines on framework conditions” adopted by the High Level Group on Joint Programming (GPC) on 11 November 2012.
- Avoiding unnecessary duplication of research and infrastructure investment at national level
- Fostering a transnational, multi-disciplinary approach to demographic change and using of the potential of societal change in Europe
- Facilitating implementation measures based on the Strategic Research Agenda of the JPI

**Type of action:** Coordination and support actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 4 – 2014: Support for international infectious disease preparedness research**

**Specific Challenge:** Human health worldwide is increasingly threatened by potential epidemics caused by existing, new and emerging infectious diseases, including those which are resistant to antimicrobial agents. An infectious epidemic can strike anywhere, and at any time globally. In order to save lives, the research response needs to be quick, flexible, comprehensive and global and therefore is beyond the capacity of any single country or even the European Union. Besides being a major threat to human health, such epidemics are a severe burden on the global economy with an impact on competitiveness, growth and jobs.

In response to these challenges a global, multi-funder initiative has been launched, the global research collaboration for infectious disease preparedness (GloPID-R). Support is therefore required in building, maintaining and coordinating a global consortium of funding organisations working towards the goal of preparing for a rapid joint global research response to any new outbreak.

**Scope:** Proposals should provide organisational support to the implementation of GloPID-R, in close collaboration with the European Commission, research funding agencies from Member States and from non-EU countries. Proposals should foresee mapping of GloPID-R relevant networks worldwide.

Proposals should assist the GloPID-R executive committee, notably for the organisation of and reporting on meetings (e.g. ad hoc meetings of working groups), support information exchange among all members of the participating bodies, facilitate the development of a strategic research agenda as well as the coordination among relevant research projects and initiatives. Proposals should also communicate progress of relevant research funded under Horizon 2020 and by consortium members. Proposals should also include support activities with relevant stakeholders groups and with the public at large (e.g. development of website, communication materials, etc.). Proposals should involve non-EU regions particularly affected by emerging epidemics.
The Commission considers that proposals requesting a contribution from the EU of between EUR 2 to 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** In line with the Union’s strategy for international cooperation in research and innovation, the project will contribute to implementing the Global Research Collaboration for Infectious Disease Preparedness.

Reinforced international cooperation in funding of research in new and emerging infectious diseases aiming to ensure a rapid and effective research response in case of an outbreak.

Effective operations of the global research collaboration for infectious disease preparedness consortium (GloPID-R) for 5 years.

Better mutual information and complementarity of funding/research initiatives worldwide in the area of emerging infectious diseases.

Decreased legal, regulatory, and financial barriers to the rapid mounting of a joint global research response

**Type of action:** Coordination and support actions

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 5 – 2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes**

**Specific challenge:** In the past twenty years the global death rate from diabetes has doubled and the World Health Organisation (WHO) is predicting that this will increase by two thirds by 2030. It is currently estimated that 347 million people worldwide suffer from diabetes with more than 80% from low- and middle-income countries. Of those suffering from diabetes, type 2 comprises 90% of this population around the world. Halting the rise in prevalence of diabetes has been identified as one of the 9 WHO non communicable diseases global voluntary targets to be met by Member States by 2025

With the burden of this chronic non-communicable disease ever-increasing the Global Alliance for Chronic Diseases (GACD) partnership, of which the Commission is a member, has agreed to launch a call for proposals on the prevention and treatment of type 2 diabetes, with a focus on implementation and intervention research in low- and middle-income countries and in vulnerable populations in high income countries.

---

36 COM(2012)497
Scope: Proposals must focus on type 2 diabetes. Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of type 2 diabetes in low and middle income countries, and in vulnerable populations in high income countries. Proposals must focus on existing approaches to prevention and control of type 2 diabetes rather than development of new treatments. Proposals may address prevention or treatment of specific complications of type 2 diabetes.

Proposals may focus on a wide range of prevention and/or treatment strategies. This may include programmes addressing (one of or combinations of):

- Changes to lifestyle and behaviour resulting from the provision of an environment that supports and promotes better health. This may include community-wide approaches, or other strategies targeting individuals at high risk. For example, population prevention strategies designed to address unhealthy diets and physical inactivity as risk factors for diabetes;
- Structural interventions or policies designed to promote improved health outcomes. For example, evaluating the contribution of public policies to diabetes prevention efforts, or monitoring the potential effects of such policies if adopted and implemented;
- Delivery of relevant health care and health interventions;
- Approaches to implementing accessibility of or adherence to, pharmaceutical, nutritional or other promising or proven interventions.

Proposals should focus on implementation research, to examine what works, for whom and under what contextual circumstances, and how interventions can be adapted and scaled up in ways that are accessible and equitable. Proposals may address prevention or treatment of specific complications of type 2 diabetes. Proposals may also focus on gestational diabetes. Proposals may focus on specific societal groups but a clear justification should be provided as to why the group has been chosen and how the choice will assist the funders in delivering their aim to address health inequities at a local and/or global level. Proposal should focus on implementation research into interventions for prevention and treatment of type 2 diabetes that are applicable in low resource settings. However, in some settings, proposals may incorporate work to establish baseline data on prevalence of diabetes and its risk factors to evaluate the impact of the intervention. Proposals may include these aspects if they do not duplicate existing evidence available.

All proposals should:

- Focus on research into implementation of prevention and/or treatment strategies derived from existing knowledge and research.
- Develop an improved understanding of the key barriers and facilitators at local and national levels that affect the prevention and treatment of type 2 diabetes.
• Include an assessment of equity and gender gaps in diabetes prevention and treatment.

• Demonstrate a sound understanding of the local health system context.

• Provide evidence of a health economics dimension such as cost effectiveness of the proposed intervention and its scalability.

• Describe a clear proposed pathway to embedding the intervention into policy and practice after the study which addresses how:
  o Local and/or national policy makers will be engaged both at the start of the project as well as the end.
  o The project outcomes/evidence will be utilised for the scaling up of the intervention on a local, national and international level.
  o Future scaled-up implementations will fit within the local social, cultural and economic context.
  o Identify obstacles such as inequities and equity gaps including gender that will be taken into account in the design of an implementation strategy.

• Be proposed by a multidisciplinary project team, including local researchers as co-investigators where applicable.

• Include local stakeholders such as patient groups or community groups.

• Proposals shall not include:
  o Replication of effectiveness studies and clinical trials testing the efficacy or effectiveness of new or established pharmacological agents (or combination of agents) which have wider effects than those relating to type 2 diabetes.
  o Aetiological or mechanistic studies of type 2 diabetes.
  o Phase I or Phase IIa trials.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 to 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:
• Reducing health inequalities and inequities, including gender, in the prevention and treatment of type 2 diabetes in both a local and global context.
• Pursuing knowledge translation and exchange approaches that are designed to maximize the public health benefits of research findings within different health contexts.

• Providing evidence to inform local health service providers, policy and decision makers on the effective scaling up of the interventions at the local, national and regional levels. For example, applicants could address affordability for users and the financial implications for implementing organisations and funders or might assess scalability to various socio-political contexts.

• Contribute to the Global Alliance for Chronic Diseases.

• Appropriate leveraging of existing programmes and platforms (e.g. research, data, and delivery platforms).

• Contribute to the WHO Global Action Plan on NCDs (2013-2020) as proposals will demonstrate alignment with international and/or national commitments to halt the rise in prevalence of type 2 diabetes.

• Contribute to the United Nations Millennium Development Goals.

The GACD aims to develop a network of researchers that can enhance cumulative learning across individual projects, and work towards understanding how socio-economic, cultural, geopolitical and policy contexts have influenced results and how findings might be adapted and applied in different settings. The funded researchers should meet annually to discuss their research and share information and data in order to develop approaches to standardise data collection, and wherever feasible to use these standardised approaches in their respective projects.

Type of action: Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

HCO 6 – 2015: Global Alliance for Chronic Diseases. Prevention and treatment of lung diseases

Specific challenge: The Global Alliance for Chronic Diseases will focus its 2015 call for implementation science proposals on lung diseases.

With the burden of this chronic non-communicable disease ever-increasing, the Global Alliance for Chronic Diseases (GACD37), of which the Commission is a member, has agreed to launch a call for proposals on the prevention and treatment of lung diseases, with a focus

37 http://www.gacd.org/
on intervention research in low- and middle-income countries (LMIC) and/or in vulnerable populations in high income countries (HIC).

Controlling tobacco consumption and reducing harmful environmental exposures (indoor and outdoor exposures) are among the most important interventions in lung disease.\(^{38}\)

Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide.\(^{39}\) Tobacco addiction causes about 5.4 million people death each year, and if resolute and urgent action is not taken by 2030 the epidemic will cause between 8 and 10 million deaths each year, of which over 80% occur in low- and middle-income countries (LMIC). Smoking is a major cause of inequality in health between gender, socioeconomic groups and age categories. With nicotine being highly addictive, it is important to prevent young people from taking up tobacco use. 70% of the smokers start before the age of 18 and 94% before the age of 25 years.

The precise health risk that environment exposure poses to lung diseases is not well established because of the difficulty to assess the prevalence linked to the amount of exposure. Risk assessment is further complicated by socioeconomic, age and genetic factors.

**Scope:** Proposals must focus on lung diseases and they must have an implementation science focus. They must address what works, for whom, under what contextual circumstances and are the intervention(s) adaptable and scalable in ways that are accessible and equitable. Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of lung diseases in LMIC, and/or in vulnerable populations in HIC.\(^{40}\) Proposals must focus on existing approaches to prevention and control of lung diseases or develop treatments at lower costs. They should demonstrate a sound understanding of the local health system context as well as the global cross-sectorial context.

All proposals should:

- Focus on research into implementation of prevention and/or treatment strategies derived from existing knowledge and research.
- Develop an improved understanding of the key barriers and facilitators at local and national levels that affect the prevention and treatment of lung diseases.
- Provide evidence of a health economics dimension such as cost effectiveness of the proposed intervention and its scalability.

---


40 The applicant needs to explain why the proposed population under investigation in HIC is vulnerable
• Describe a clear proposed pathway to embedding the intervention into policy and practice after the study which addresses how:
  − Local and/or national policy makers will be engaged both at the start of the project as well as the end.
  − The project outcomes/evidence will be utilised for the scaling up of the intervention on a local, national and international level.
  − Future scaled-up implementations will fit within the local social, cultural and economic context.
  − Identify obstacles such as inequities and equity gaps including gender that will be taken into account in the design of an implementation strategy.

• Include local stakeholders such as patient groups or community groups.

Proposals may focus on a wide range of prevention and/or treatment strategies. This may include programmes addressing (one of or combinations of):

• Structural interventions or policies designed to promote improved health outcomes. For example, evaluating the contribution of public policies to lung diseases prevention efforts, or monitoring the potential effects of such policies if adopted and implemented;

• Approaches to implementing accessibility of or adherence to, pharmaceutical, or other promising or proven interventions;

• Study the feasibility and effectiveness of low-cost and integrated prevention and management approaches of lung diseases;

• Study populations exposed to tobacco products\(^{41}\), in particular assessing the behaviour of populations consuming those products that may contribute to: (i) developing addiction, (ii) shifting normative attitudes to smoking and tobacco control, and (iii) establishing overall impact of those tobacco products at both individual and population levels;

• Study populations exposed to electronic cigarettes\(^{42}\), in particular assessing (i) the behaviour of populations consuming these products that may result in developing

---

\(^{41}\) Cigarettes, slim cigarettes, water pipes, smokeless tobacco, novel tobacco products.

\(^{42}\) As defined in Article 2(16) of the Tobacco Products Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014, 'electronic cigarette' means a product that can be used for consumption of nicotine-containing vapour via a mouth piece, or any component of that product, including a cartridge, a tank and the device without cartridge or tank. Electronic cigarettes can be disposable or refillable by means of a refill container and a tank, or rechargeable with single use cartridges.
addiction to nicotine; (ii) the overall public health impact of electronic cigarettes over long term and address questions to what extent these products are an initiation product to/cessation product from nicotine addiction and tobacco consumption.

- Assess current policy for prevention (e.g. design/presentation, fiscal, tax and information policy related to tobacco) as well as options to support smoking cessation (including pharmacotherapy, electronic cigarettes, intervention financing mechanisms), taking into account the context in which they are implemented. Research on new low cost formulations of proven effective therapies will also be supported;

- Optimize tobacco cessation interventions, identify the most cost-effective interventions for resource-constrained settings and integrate smoking cessation into health systems;

- Evaluate the impact of interventions for reducing environmental exposure and mitigating their effects in indoor and outdoor air pollution;

- Investigate the interaction between the individual and the environment to better define at-risk populations and identify biomarkers for lung diseases associated with environmental exposure;

- Propose intervention(s) to modify indoor and outdoor exposures and assess the subsequent health outcome.

The GACD aims to develop a network of researchers that can enhance cumulative learning across individual projects, and work towards understanding how socio-economic, cultural, geopolitical and policy contexts have influenced results and how findings might be adapted and applied in different settings. The funded researchers should meet annually to discuss their research and share information and data in order to develop approaches to standardise data collection, and wherever feasible to use these standardised approaches in their respective projects.

The Commission considers that proposals requesting a contribution from the EU of between EUR 1 to 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- To demonstrate the link between the intervention(s) and health outcome in lung diseases;

- To reduce health inequalities and inequities, including gender, in the prevention and treatment of lung diseases in both a local and global context;
To pursue knowledge translation and exchange approaches that are designed to maximize the public health benefits of research findings within different health contexts;

To provide evidence to inform local health service providers, policy and decision makers on the effective scaling up of the interventions at the local, national and regional levels. For example, applicants could address affordability for users and the financial implications for implementing organisations and funders or might assess scalability to various socio-political contexts;

Appropriate leveraging of existing programmes and platforms (e.g. research, data, and delivery platforms);

To improve quality controls and safety (including toxicity profile) of tobacco products and electronic cigarettes;

To develop the necessary knowledge basis for further coordination of regulatory aspects related to tobacco products and electronic cigarettes;

To characterise behavioural group specificity in successful intervention(s) in order to tailor preventive and control interventions;

To develop lower cost therapeutic option for smoking cessation that are cost effective in LMIC;

To contribute to the United Nations Millennium Development Goals.

**Type of action:** Research and innovation actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

---

**HCO 7 – 2014: ERA-NET: Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020**

**Specific challenge:** The EU Joint Programming Initiative on Neurodegenerative Diseases Research, in particular Alzheimer’s (JPND), was established in 2009 as the pilot of the Member State-led Joint Programming Initiatives and enables the participating EU Member States to work together on the challenge of age-related neurodegenerative diseases. JPND allows the establishment, alignment and building on of national research programmes to increase the effectiveness and impact of research efforts.

---

The JPND Research Strategy must now be scaled-up and synergies must be established with Horizon 2020 as was also called for by the Council in its conclusions of 8 December 2011[44]. The scope of the Research Strategy requires coordinated action not only amongst the participating countries but also with the EC for producing the necessary critical mass. Moreover, for achieving the highest impact possible, there is the need for less fragmentation, better coordination and alignment amongst the countries participating in the JPND.

Scope: Proposals should coordinate national and regional programmes for research in the area of neurodegenerative diseases research by implementing a transnational call with EU co-funding resulting in grants to third parties, with a view to scale-up the implementation of the JPND Research Strategy. This call shall be defined as follows: ‘Identification of genetic, epigenetic and environmental risk and protective factors for neurodegenerative diseases’, and/or of the ‘Longitudinal cohorts in neurodegenerative disease research’ and/or of the ‘Advanced experimental models of neurodegenerative diseases’.

Proposals should also promote the strategic alignment of research activities related to neurodegenerative diseases across Europe, such as developing and aligning national research plans and strategies, making data bases more accessible and interoperable, harmonisation of measurements and methodologies, networking of already existing structures and studies, training etc.

Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposal should implement other joint activities including training and additional joint calls without EU co-funding.

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Funding of research proposals on a topic identified by the JPND implementation plan or by their action groups, which needs to be addressed at European level and which is complementary to topics of the EC work programmes;
- Leverage transnational excellent research with EU-added value in the area of neurodegenerative diseases;
- Increased commitment of participating countries to the implementation of the JPND SRA;
- Establishment and alignment of national and regional plans and initiatives on neurodegenerative diseases;
- Strengthened exchange and better interoperability between existing European infrastructures and databases;
- Enhancement and/or better exploitation of national or EC-supported activities.

**Type of action:** ERA-NET Co-fund

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 8 – 2014: ERA-NET: Aligning national/regional translational cancer research programmes and activities**

**Specific challenge:** The challenges in the area of translational cancer research can only be met by an effective cooperation at transnational level avoiding the duplication of efforts, by ensuring the availability of critical mass, by efficiently using available resources, by exchanging knowledge, by producing more significant results of higher quality and impact, and sharing data and infrastructures.

Significant progress has been made in this respect by existing initiatives. There is however still the need for better coordination, data sharing and alignment of national programmes and activities in the above mentioned area.

**Scope:** Proposals should coordinate national and regional programmes for research in the area of translational cancer research by implementing a transnational call with EU co-funding resulting in grants to third parties.

Proposals should also aim at the better collaboration and alignment of national programmes and activities and should provide concrete plans for decreasing fragmentation, for data sharing, for addressing hurdles for effective coordination, for involving stakeholders and relevant existing initiatives. The proposal should consider and may build on previous EU-funded projects supporting ERA-NETs.

Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposals should implement other joint activities including training and additional joint calls without EU co-funding.
The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Stepping up funding of transnational collaborative research projects in the area of translational cancer research;
- Identification of common research priorities and research needs, also taking into account developments on the international level where relevant;
- Establishment and/or implementation of a common strategic research agenda;
- Development and alignment of national and regional plans;
- Streamlined national or regional practices in organising research funding;
- Increased interoperability of national research programmes;
- Prioritisation of transnational research;
- Sharing of data and knowledge;
- Networking of infrastructures and databases;
- Contribution to the establishment of the ERA by addressing issues related for example to administrative hurdles, IPR management and different practices regarding resource sharing.

**Type of action:** ERA-NET Co-fund

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 9 – 2014: ERA-NET: Systems medicine to address clinical needs**

**Specific challenge:** The rise of genomics and the accumulation of large amounts of data potentially provide medicine with many new opportunities. With this abundance of different types of data has come the realisation that a full understanding of disease processes requires research that integrates and interprets data at the system level.
Through the seventh framework programme, co-ordination action CaSyM\textsuperscript{45}, health research funders, clinicians, researchers, medical educators and industry, have agreed a road map that prioritises areas where a systems approach is needed to address clinical questions and solve clinical problems. EU policy makers also recognise the need for systems medicine in the drive to make personalised medicine a reality (Commission draft report on use of –omics technologies in the development of personalised medicine).

Scope: Proposals should aim to coordinate national and regional programmes for research in the area of systems medicine. Proposals should implement a transnational call with EU co-funding, resulting in grants to third parties, with a view to support multinational innovative research initiatives on the research priorities identified in the CaSyM action.

Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposals should implement other joint activities including training and additional joint calls without EU co-funding.

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This ERA-NET will:

- improve cooperation and synergies between national and regional efforts, including mutual opening of national programmes,
- suggest new paths for clinical research aiming at delivering better prevention and more efficient and personalised therapies throughout life
- support the European Policy for the development of personalised medicine
- improve knowledge of health and disease focussed on helping clinical decision making
- make best use of national and EU funding in relevant areas of research and ensure better use of limited resources
- develop training activities and European curriculum for systems medicine

\textsuperscript{45} https://www.casym.eu/
Type of action: ERA-NET Co-fund

The conditions related to this topic are provided at the end of this call and in the General Annexes

HCO 10 – 2014: ERA NET: Rare Disease research implementing IRDiRC objectives

Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020\(^46\). An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.

Scope: Proposals should coordinate national and regional programmes for research on rare diseases by preparing and implementing a transnational call with EU co-funding, resulting in grants to third parties, with a view to implement IRDiRC\(^47\) objectives and identified priorities. This call should aim at furthering the understanding of disease mechanisms and natural history of rare diseases with the objective to develop new diagnostic tools and treatments. Selected proposals should adhere to the policies and guidelines of IRDiRC.

Proposals should be complementary with other funding programmes and activities on European and international level.

Proposals should demonstrate the expected impact on national and transnational programmes and IRDiRC objectives as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposals should also aim at implementing other joint activities including training and additional joint calls without EU co-funding.

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

\(^{46}\) [www.irdirc.org](http://www.irdirc.org)

\(^{47}\) The IRDiRC policies and guidelines document is available on: [http://www.irdirc.org/?page_id=12](http://www.irdirc.org/?page_id=12)
In line with the Union’s strategy for international cooperation in research and innovation\(^{48}\), the project will contribute to reaching the overall goals of IRDiRC;

- Deepened and extended coordination of national and transnational research in the field of rare diseases resulting in a substantial contribution to the overall goals of IRDiRC;
- Streamlined national/regional and international practices in organising research funding;
- Increased interoperability of national research programmes;
- Increased sharing of data and knowledge;
- Increased networking of infrastructures and databases.

**Type of action: ERA-NET Co-fund**

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 11 – 2015: ERA-NET: Collaboration and alignment of national programmes and activities in the area of brain-related diseases and disorders of the nervous system**

**Specific challenge:** The challenges in the areas of brain-related diseases can only be met by an effective cooperation at transnational level avoiding the duplication of efforts, ensuring the availability of critical mass, efficiently using available resources, exchanging knowledge, producing more significant results of higher quality and impact, and sharing data and infrastructures.

Significant progress has been made in this respect by existing initiatives. However there is still the need for better coordination, data sharing and alignment of national programmes and activities in the abovementioned areas.

**Scope:** Proposals should coordinate national and regional programmes for research in the area of brain-related diseases by implementing a transnational call with EU co-funding resulting in grants to third parties.

Proposals should also aim at improved collaboration and alignment of national programmes and activities and will provide concrete plans for decreasing fragmentation, for data sharing, for promoting common data elements for the establishment of patient registries, for addressing hurdles for effective coordination, for involving stakeholders and relevant existing initiatives. Proposals should consider and may build on previous EU-funded projects supporting ERA-NETs.

\(^{48}\) COM(2012)497
Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposal should implement other joint activities including training and additional joint calls without EU co-funding.

The Commission considers that proposals requesting a contribution from the EU a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Stepping up funding of transnational collaborative research projects in the areas of brain-related diseases;
- Identification of common research priorities and research needs, also taking into account developments on the international level where relevant;
- Establishment and/or implementation of a common strategic research agenda;
- Development and alignment of national and regional plans;
- Streamlined national or regional practices in organising research funding;
- Increased interoperability of national research programmes;
- Prioritisation of transnational research;
- Sharing of data and knowledge;
- Networking of infrastructures and databases;
- Contribution to the establishment of the ERA by addressing issues related for example to administrative hurdles, IPR management and different practices regarding resource sharing.

**Type of action:** ERA-NET Co-fund

*The conditions related to this topic are provided at the end of this call and in the General Annexes*

**HCO 12 – 2015: ERA-NET: Antimicrobial Resistance**
Specific challenge: Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. In Europe, however, research on the resistance to antibiotics and on how to make sustainable use of antibiotics is fragmented. In addition, few countries have specific programs dedicated to this field of research.

The Joint Programming Initiative (JPI) on Anti-Microbial Resistance (AMR) provides an excellent opportunity for joint research of the EU Member States addressing the emerging problem of antibiotic resistance in human and veterinary medicine. Indeed, the currently funded research projects in national or trans-national programs are usually the result of calls initiated within other research areas rather than from research programmes specifically focusing on AMR. Consequently, the variable and non-permanent resources of trans-national organisations and individual countries are insufficient to provide the long-term funding opportunities that are required to solve the major research questions concerning AMR. In addition, research activities on AMR are not harmonised between countries; which may lead to duplications in the research being performed in different countries.

The 19 participating countries of the AMR JPI aim to accomplish the coordination of European research on AMR in close collaboration with the funding instruments of the EU; specifically Horizon 2020, Innovative Medicines Initiative (IMI) and the ERA-NET Infect-ERA.

This will create the necessary critical mass and develop the most advanced scientific approaches to tackle the problem of AMR, reversing its increasing trend, in the way forward defined by the Strategic Research Agenda which is to be adopted by the JPIAMR in early 2014.

This transnational cooperation will enhance the societal impact that is required in this area, promoting knowledge dissemination among multiple sectors of the society that are implicated – patients, clinical, veterinarians, pharmacists, food producers and representatives of the pharmaceutical industry.

Scope: Proposals should be central to the effective coordination of joint research funding in the area of AMR. Proposals should coordinate national and regional programmes in order to implement the Strategic Research Agenda (SRA) of the JPI AMR through a transnational call with EU co-funding resulting in grants to third parties.

This transnational call topic should be in line with one or more of the priority areas of the SRA and is expected to lead to a lower, smarter use of antibiotics in veterinary and clinical settings and to a significant reduction of the risk that antibiotic-resistance poses to public health.
Proposal should implement other joint activities including collaborative actions with the World Health Organisation or the pharmaceutical industry (among others) as well as additional joint international calls without EU co-funding (e.g. with Canada).

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

- Leverage transnational research by funding research proposals on a topic identified by the JPIAMR from its Strategic Research Agenda and implementation plan.
- Stimulate and increase research into the causes, prevention, diagnosis and treatment of infections caused by resistant organisms and force the EU added value in the area of antibiotics.
- Enhancement and/or better exploitation of current research funding activities at national, European and international level.
- Catalysing and strengthening the development of national and trans-national strategies in JPI AMR countries.
- Establishment and alignment of existing national strategies.
- Increased visibility, also at a political level, of the burden of AMR and the benefits of research to economy and society.

Type of action: ERA-NET Co-fund

The conditions related to this topic are provided at the end of this call and in the General Annexes

HCO 13 – 2015: ERA-NET: Cardiovascular disease

Specific challenge: Cardiovascular diseases (CVD) are the largest cause of death in the EU and account for 40% of deaths or 2 million deaths per year. Overall CVD is estimated to cost the EU economy almost EUR 110 billion a year, and they are also one of the leading causes of long term sickness and loss to the labour market. CVD is therefore a major health problem in every country in Europe.

Despite this overall burden, research into CVD is fragmented. In addition, few countries have specific programs dedicated to this field of research.

The challenges in the area of cardiovascular research can only be met by an effective cooperation at transnational level avoiding the duplication of efforts, ensuring the availability of critical mass, efficiently using available resources, exchanging knowledge, producing more significant results of higher quality and impact, and sharing data and infrastructures.
**Scope:** Proposals should coordinate national and regional programmes for research in the area of cardiovascular research by implementing a transnational call with EU co-funding resulting in grants to third parties. Moreover, proposals should also aim at the better collaboration and alignment of national programmes and activities and should provide concrete plans for decreasing fragmentation, for data sharing, for addressing hurdles for effective coordination, for involving stakeholders and relevant existing initiatives.

Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

Proposals should implement other joint activities including training and additional joint calls without EU co-funding.

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Stepping up funding of transnational collaborative research projects in the area of cardiovascular research;
- Identification of common research priorities and research needs, also taking into account developments on the international level where relevant;
- Establishment and/or implementation of a common strategic research agenda;
- Development and alignment of national and regional plans;
- Streamlined national or regional practices in organising research funding;
- Increased interoperability of national research programmes;
- Prioritisation of transnational research;
- Sharing of data and knowledge;
- Networking of infrastructures and databases;
- Contribution to the establishment of the ERA by addressing issues related for example to administrative hurdles, IPR management and different practices regarding resource sharing.

**Type of action:** ERA-NET Co-fund
The conditions related to this topic are provided at the end of this call and in the General Annexes

HCO 14 – 2014: Bridging the divide in European health research and innovation

Specific challenge: The research and innovation potential of the Member States remain very different, with large gaps between “innovation leaders” and “modest innovators”. This divide is equally present in European health research and innovation.

Two major European instruments – the Research Framework Programme and the Structural Funds – attempt to address this issue, albeit from distinct perspectives, but with the same strategic goals of serving the Europe2020 strategy for smart, sustainable and inclusive growth.

There is no one-size-fits-all solution. Therefore, new approaches specific to health research and innovation are needed that take into account the individual differences of the less performing RDI regions and provide tailor-made recommendations.

Scope: To tackle successfully the divide in European health research, both evidence based analysis and remedial actions are needed. Proposals may address either analysis or remedial actions, or both.

Proposals should examine the current health research activities in the less performing RDI regions/countries, looking into determinants influencing the health R&I performance. Strategies of these regions (RIS3 – Research and Innovation Strategies for Smart Specialisation) can be studied, and specific indicators can be identified to measure development. Proposals should reveal the factors underlying the divide; identify common patterns and individual differences within these regions. Outcomes should include suggested European and local actions to alleviate differences in health R&I.

For remedial actions, proposals should develop new approaches to unlock excellence in those regions.

Proposals should create a networking platform where companies, research organisations, universities, national authorities and managers of H2020 and structural funds can talk to each other to identify the needs, obstacles, best practice, opportunities.

The Commission considers that proposals requesting a contribution from the EU of up to EUR 500,000 would allow this specific challenge to be addressed appropriately. Nonetheless this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: Within the health R&I domain, the action(s) should contribute to three important Horizon 2020 goals:

- Widening participation
- Bridging the innovation divide
- Synergies between H2020 and Structural Funds
**Type of action:** Coordination and support actions

The conditions related to this topic are provided at the end of this call and in the General Annexes

**HCO 15 – 2014: Mobilisation and mutual learning action plan**

**Specific challenge:** Ensuring that research and innovation in this societal challenge is not only excellent, but also relevant and responsive to the needs of all is important, not least in ensuring the uptake of results.

**Scope:** Mobilisation and Mutual Learning Action Plans (MML) are one means of ensuring the engagement of all relevant groups and aim to tackle research and innovation related challenges by creating partnerships with a variety of perspectives, knowledge and experience.

MMLs are Coordination and Support Actions (CSA) with at least 10 countries that allow discussion and cooperation between science and society at different stages of the research and innovation process. MMLs comprise at least one of each of the following types of partners: research performing or funding organisations, industry/businesses, policy makers, Civil Society Organisations. The consortium may also include media, education establishments, science academies, museums, science centres, etc. Ensuring a balanced distribution of roles and responsibilities between the different types of participants shall be evaluated under evaluation criterion 2.

The Commission considers that proposals requesting a contribution from the EU of up to EUR 1 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:** The MML should contribute to the implementation of ‘Science with and for Society’ issues (public engagement, ethics, gender perspectives, science education, communication and access to and dissemination of scientific information) in the area of health. It should develop a common communication and implementation strategy to further the implementation of the MML outcomes and recommendations. It should contribute to relevant EU related initiatives and policy developments at local, national and European levels.

**Type of action:** Coordination and support actions

**HCO 16 – 2014: National Contact Points**

**Specific challenge:** Facilitate trans-national co-operation between NCPs within this societal challenge with a view to identifying and sharing good practice and raising the general
standard of support to programme applicants, taking into account the diversity of actors that make up the constituency of this societal challenge.

Scope: Support will be given to a consortium of formally nominated NCPs in the area of this societal challenge. The activities will be tailored according to the nature of the area, and the priorities of the NCPs concerned. Various mechanisms may be included, such as benchmarking, joint workshops, enhanced cross-border brokerage events, specific training linked to this societal challenge as well as to gender dimension of Research and Innovation, and twinning schemes. Special attention will be given to enhance the competence of NCPs, including helping less experienced NCPs rapidly acquire the know-how accumulated in other countries. Liaison with other support structures, projects and programmes (e.g., IMI2, EDCTP2, IPR helpdesk, EEN, EMA) should be detailed in the proposal.

The focus throughout should be on issues specific to this societal challenge and should not duplicate actions foreseen in the NCP network for quality standards and horizontal issues under ‘Science with and for Society’.

Only NCPs from EU Member States and Associated Countries (and other countries only where fully justified) which have been officially appointed by the relevant national authorities are eligible to participate in and receive funding for this action.

The consortium should have a good representation of experienced and less experienced NCPs.

Submission of a single proposal is encouraged. NCPs from EU Member States or Associated Countries choosing not to participate as a member of the consortium should be identified and the reason explained in the proposal. These NCPs are nevertheless invited and encouraged to participate in the project activities (e.g. workshops) and the costs incurred by the consortium for such participation (e.g. travel costs paid by the consortium) may be included in the estimated budget and be eligible for funding by the Commission.

The Commission will only fund one proposal under this topic.

Expected impact:

- An improved and professionalised NCP service across Europe, thereby helping simplify access to Horizon 2020 calls, lowering the entry barriers for newcomers, and raising the average quality of proposals submitted.
- A more consistent level of NCP support services across Europe.

Funding scheme: Coordination and support action

Evaluation criteria and rate of co-financing: The standard evaluation criteria, thresholds, weighting for award criteria and the maximum rate of co-financing for this type of action are provided in parts D and H or the general annexes.
HCO 17 – 2015: Towards sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases

Specific challenge: The EU Joint Programming Initiative on Neurodegenerative Diseases Research, in particular Alzheimer's (JPND), was established in 2009 as the pilot of the Member State-led Joint Programming Initiatives (JPI) to enable the participating EU Member States to work together on the challenge of age-related neurodegenerative diseases. Throughout the past five years, the JPND has proved an important tool for the establishment of a European Research Area in this field. The JPND has made considerable progress in enabling Member States to pursue common visions, and contributed greatly to increasing awareness and creating an unprecedented mobilization of human resources, actions, and funding to tackle the challenge of neurodegenerative diseases. The HCO 7 – 2014 topic calling for an ERA-NET provides opportunity to the JPND to leverage the support for the implementation of its Strategic Research Agenda, as well as to network and align Members’ research activities.

Another immediate challenge for the JPND is managing and extending its capacities. In this context, the JPND should capitalize on the current momentum to take the necessary management steps for securing its sustainability by Member States, to extend globally and mobilize the Members States which are not yet participating in the JPND, and to take up actions at the national level. The JPND’s major achievements and expected future developments call for careful planning for its long-term sustainability, in particular because as the pilot JPI, the JPND is paving the way for other JPIs. A sustainable structure should allow the JPND to progressively move from coordination to integration of national research activities, to further develop its visibility at global level, and to facilitate greater innovation to improve the quality of life for people with neurodegenerative diseases and their carers while reducing emotional and financial burden.

Scope: Proposals should support the development and extension of the JPND capacities. In particular, resources should be used to:

- Explore possible scenarios for long-term sustainability by Member States and create political awareness to prepare their implementation. The project should also dedicate resources to develop and implement a dedicated structure responsible for the long-term JPND management and implementation;
- Extend the capacities of the JPND globally and to the Members States which are not yet participating in the JPND. For this purpose, the project should dedicate resources to implement its global strategy and develop a strategy to attract and raise awareness of the missing EU-13 Member States. This should include identification of available national research & innovation resources in the area of neurodegenerative diseases;
- Develop and implement current and new strategies for further coordination of national and JPND research agendas, and in particular for the take-up of JPND strategies and policies at national level. This should clearly demonstrate the leverage effect of the JPND. In this context, the project should dedicate resources to develop and implement initiatives for
knowledge management, brokerage and transfer, as well as establishing collaborations with other initiatives or partners at European and global level;

- Provide innovative strategies for the creation of infrastructures and tools to facilitate more rapid uptake of data and methodologies for research on neurodegenerative diseases in EU and beyond;
- Facilitate building networks of industrial and academic experts to boost industrial innovation in the field of neurodegenerative diseases research in Europe in collaboration with IMI.

The proposal should not duplicate work already covered under HCO 7. The Commission considers that proposals requesting a contribution from the EU of between EUR 1 to 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected impact:**

- Reinforcing the JPI scheme as a major tool for the achievement of the European Research Area;
- Implementing a stronger global dimension of the JPND, aligned with the G8 summit on dementia recommendations⁴⁹;
- Increased multiannual commitment of JPND members, long-term sustainability of the JPND research and innovation strategy, and long-term structuring effect and critical mass mobilization;
- Achieving coordination and integration of national research & innovation programmes with the JPND research strategy in coherence with Horizon 2020 objectives;
- Faster international progress for research and innovation on neurodegenerative diseases through the development of novel research tools and infrastructures;
- Increasing efficiency of research and innovation investments by European Member States by avoiding duplication of research and infrastructure investment at national level;
- Awareness and potential extension of the JPND to missing EU-13 Member States;
- Further establishing the JPND as a reference for European and global knowledge and innovation platform in the area of neurodegenerative diseases.

**Type of action:** Coordination and support action

⁴⁹ https://www.gov.uk/government/publications/g8-dementia-summit-agreements
**CONDITIONS FOR THIS CALL**

**Opening dates**\(^{50}\):  
- 11 December 2013 for 2014 topics  
- 30 July 2014 for 2015 topics

**Deadline**\(^{51}\): 15\(^{th}\) April 2014 for 2014 topics and 24 February 2015 for 2015 topics

<table>
<thead>
<tr>
<th>HCO 1 - 2014</th>
<th>15(^{th}) April 2014 at 17.00.00 Brussels time</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCO 2 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 4 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 5 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 7 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 8 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 9 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 10 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 14 – 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 15 – 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 16 - 2014</td>
<td></td>
</tr>
<tr>
<td>HCO 6 - 2015</td>
<td>24 February 2015 at 17.00.00 Brussels time</td>
</tr>
<tr>
<td>HCO 11 - 2015</td>
<td></td>
</tr>
<tr>
<td>HCO 12 - 2015</td>
<td></td>
</tr>
<tr>
<td>HCO 13 - 2015</td>
<td></td>
</tr>
<tr>
<td>HCO 17 - 2015</td>
<td></td>
</tr>
</tbody>
</table>

**Indicative budget:**

- EUR 40.00 million from the 2014 budget  
- EUR 29.00 million from the 2015 budget\(^{52}\)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HCO 2 – 2014</td>
<td>2.00</td>
<td></td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 4 – 2014</td>
<td>3.00</td>
<td></td>
<td>Single stage</td>
</tr>
</tbody>
</table>

---

\(^{50}\) The Director-General responsible may decide to open the call up to one month prior to or after the envisaged date of opening.

\(^{51}\) The Director-General responsible may delay this deadline by up to two months.

\(^{52}\) The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.
### Eligibility and Admissibility Conditions

The conditions are described in parts B and C of the General Annexes to the work programme.

### Evaluation Criteria, Scoring, and Threshold

The criteria, scoring, and threshold are described in part H of the General Annexes to the work programme, with the following exceptions.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Amount</th>
<th>Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCO 5 -2014</td>
<td>9.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 6 -2015</td>
<td>12.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 7 - 2014</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 8 – 2014</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 9 – 2014</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 10 - 2014</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 11 – 2015</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 12 - 2015</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 13 – 2015</td>
<td>5.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 14 - 2014</td>
<td>1.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 15 - 2014</td>
<td>1.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 16 - 2014</td>
<td>2.00</td>
<td>Single stage</td>
</tr>
<tr>
<td>HCO 17 - 2015</td>
<td>2.00</td>
<td>Single stage</td>
</tr>
<tr>
<td><strong>TOTALS</strong></td>
<td>40.00</td>
<td>29.00</td>
</tr>
</tbody>
</table>

If a proposal fails to achieve the threshold for a criterion, the evaluation of the proposal will be stopped.

### Evaluation Procedure

The procedure for setting a priority order for proposals with the same score is given in part H of the General Annexes.

---

53 For topic HCO 6, beneficiaries will be allowed to charge the cost of clinical trials on the basis of unit costs established in line with the methodology set up in the COMMISSION DECISION (C(2014) 1393 final) of 07.03.2014 authorising the use of reimbursement on the basis of unit costs for actions requiring the conduct of clinical studies under ‘Societal Challenge 1: Health, Demographic Change and Wellbeing’ of the Horizon 2020 Framework Programme.
The full evaluation procedure is described in the relevant guide\textsuperscript{54} published on the Participant Portal.

- Indicative timetable for evaluation and grant agreement:

<table>
<thead>
<tr>
<th>Consortia</th>
<th>Information on the outcome of the evaluation (single stage)</th>
<th>Information on the outcome of the evaluation (second stage)</th>
<th>Indicative date for the signing of grant agreements</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCO 1 - 2014, HCO 2 - 2014, HCO 4 - 2014, HCO 5 - 2014, HCO 7 - 2014, HCO 8 – 2014, HCO 9 - 2014, HCO 10 - 2014, HCO 14 - 2014, HCO 15 – 2014, HCO 16 - 2014</td>
<td>Maximum 5 months from the final date for submission</td>
<td>n/a</td>
<td>Maximum 3 months from the date of informing applicants</td>
</tr>
<tr>
<td>HCO 6 - 2015, HCO 11 - 2015, HCO 12 - 2015, HCO 13 - 2015, HCO 17 - 2015</td>
<td>Maximum 5 months from the final date for submission</td>
<td>n/a</td>
<td>Maximum 3 months from the date of informing applicants</td>
</tr>
</tbody>
</table>

Consortium agreements: In line with the Rules for Participation and the Model Grant Agreement, participants in Research and Innovation Actions or in Innovation Actions are required to conclude a consortium agreement prior to grant agreement.

Fast track to innovation pilot

Full details on this pilot are provided in the separate call for proposals under the Horizon 2020 Work Programme Part - Fast Track to Innovation Pilot (Part 18 of this Work Programme).
Other actions

HOA 1 – 2014/2015: Subscription fee: Human Frontier Science Programme Organisation

Scope: An annual subscription to the international Human Frontier Science Programme Organisation (HFSPO) will allow EU non-G8 Member States to fully benefit from the Human Frontier Science Programme (HFSP) and provide increased visibility for European research, as well as contributing to the implementation of the Union’s strategy for international cooperation in research and innovation.

Type of action: Subscription

Indicative timetable: 2014 and 2015

Indicative budget: EUR 4 765 000 from the 2014 budget and of EUR 4 861 000 from the 2015 budget

HOA 2 – 2014/2015: Tenders for programme evaluation, studies and impact assessment, Scientific Panel for Health, and for conferences, events and outreach activities.

Scope: A number of specific contracts will be signed under existing framework contracts in order to support the monitoring and evaluation of previous Framework Programme activities of relevance to this societal challenge, and of the societal challenge itself; to support dissemination and exploitation of project results; in order to contribute to the definition of future challenge priorities; and to organise conferences (the subjects of which may include but are not limited to the European Innovation Partnership on Active and Healthy Ageing and eHealth, and the annual Conference of the Scientific Panel for Health), events and outreach activities. Six such contracts are currently foreseen, four to start in the second semester of 2014, and the remaining two in 2015. Should existing framework contracts prove unsuitable or insufficient to support the abovementioned activities, one or more calls for tender may be

---

55 The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.

56 The European Union is a member of the HFSP Organisation (HFSPO) and has funded HFSP under previous Framework Programmes

57 COM(2012)497

58 The Scientific Panel for Health is mandated by Regulation (EU) No 1291/2013 establishing Horizon 2020
invited as appropriate. This will be the case for the establishment and operations of the independent secretariat of the Scientific Panel for Health.

**Type of action:** Public procurement

**Indicative timetable:** Second semester 2014; 2015

**Indicative budget:** EUR 4.70 million from the 2014 budget; EUR 3.65 million from the 2015 budget.

---

**HOA 3 – 2014/2015: Presidency events - eHealth**

A maximum of EUR 300,000 will be allocated to one Presidency in each year (in 2014, to the Greek Presidency and in 2015 to the Latvian Presidency), for the organisation of a conference focusing on eHealth.

**Legal entity:**


**Type of action:** Grant to identified beneficiary – Co-ordination and support actions.

**Evaluation and rate of co-financing:** The standard evaluation criteria, thresholds, weighting for award criteria and the maximum rate of co-financing for this type of action are provided in parts D and H of the General Annexes.

**Indicative timetable:** First semester 2014; and 2015

**Indicative budget:** EUR 300 000 from the 2014 budget, EUR 300 000 from the 2015 budget.

---

**HOA 4 – 2014/15: Independent experts assisting in proposal evaluations and assessment, and project reviews**

This action will support the use of appointed independent experts for the evaluation of project proposals and, where appropriate, for the monitoring of running projects, as well as for the evaluation of entries submitted to prize contests and of the annual work plan of EDCTP2.

**Type of action:** Expert contracts

**Indicative budget:** EUR 7.83 million from the 2014 budget; EUR 7.89 million from the 2015 budget.
HOA 5 – 2014: Grant to the Global Alliance for Chronic Diseases

Scope: The European Commission will make a contribution towards activities of the Global Alliance for Chronic Diseases (GACD). This will enable the European Commission to take part in GACD, which brings together leading health research funding agencies of key countries (currently USA, Australia, UK, Canada, China, India, and South Africa) to coordinate research activities addressing on a global scale the prevention and treatment of chronic, non-communicable diseases such as cardiovascular diseases (mainly heart disease and stroke), diabetes, mental health and cancer. Recommendations of GACD are expected to have a fundamental value for future orientation of public health research policy. This will also contribute to the implementation of the Union’s strategy for international cooperation in research and innovation.

Legal entity: Funding will be provided through an action grant to the secretariat of the GACD, hosted by University College London (UCL), Gower Street 1, WC1E 6BT, London, UK.

Form of funding: Grant to identified beneficiary – coordination and support actions.

Evaluation and rate of co-financing: The standard evaluation criteria, thresholds, weighting for award criteria and the maximum rate of co-financing for this type of action are provided in parts D and H or the general annexes.

Indicative timetable: 2014

Indicative budget: EUR 180 000 from the 2014 budget

HOA 6 – 2014: Stem cell research outreach

Specific challenge: Stem cell research offers hope for untreatable and life-threatening disease, however the use of these cells raises ethical concerns which vary across Europe and which make the research the subject of great debate among scientists, clinicians, religious groups, business interests and the public in general.

In order to inform the general public about this research, its results and perspectives, the EU has supported under the seventh framework programme a coordination and support action called Eurostemcell, whose centrepiece is a multi-lingual website, the European Stem Cell Information Portal www.eurostemcell.org.

The debate about stem cell research during the run-up to H2020 coupled with new scientific discoveries that are opening up new treatment approaches and applications demonstrate the continuing need to provide information and scientific outreach to the European public.

59 COM(2012)497
University of Edinburgh is identified as the beneficiary to carry out this work because it has set up the existing web portal, kept it up-to-date and fed it with new material during the course of the seventh framework programme. The portal built up by the beneficiary during the seventh framework programme meets the requested communication and outreach objectives effectively. The objective is to ensure continuation of the existing portal.

Scope: The information portal has developed into the premier European reference site for stem cell information and discourse. The consortium comprises the principal stem cell laboratories across Europe, including new member states, and additionally offers outstanding expertise in ethical and societal concerns and in evaluating clinical outcomes. This coalition provides unparalleled expertise across the field of stem cell biology and regenerative medicine, and is uniquely placed to achieve the vision of a trusted and accessible European stem cell information resource that promotes and facilitates public dialogue.

Expected impact: Continuation of Eurostemcell web portal as a European reference point for stem cell research;

Dissemination of results of EU projects and other stem cell research to general audiences;

Multi-lingual provision of factual information about stem cell research, including ethical and societal considerations;

Provision of trusted high quality information on stem cells accessible to citizens and stakeholders across Europe;

Stronger European presence on web-based information on stem cell research;

Better information flow between European stem cell researchers;

Strengthen European efforts to exploit scientific results in stem cell research for the benefit of patients.

Legal entity: University of Edinburgh, Edinburgh EH8 9YL, UK.

Type of action: Grant to identified beneficiary - coordination and support actions

Evaluation criteria and rate of co-financing: The standard evaluation criteria, thresholds, weighting for award criteria and the maximum rate of co-financing for this type of action are provided in parts D and H or the general annexes.

Indicative timetable: 2014

Indicative budget: EUR 0.60 million from the 2014 budget
HOA 7 – 2015: eHealth Inducement Prize: Food scanner

The objective of this inducement prize is to unlock the eHealth market with solutions that support citizens in adopting a more active and healthier lifestyle and in improving the quality of their health condition by better monitoring of their food intake. The specific rules of the contest will be published in 2015 by the European Commission, which will directly launch and manage the contest and award the prize based on the judgement of independent experts.

Expected results:
An eHealth solution that enables citizens to precisely, timely and efficiently assess their food intake and provides optimal recommendations to improve their health and well-being. The solution should benefit a wide range of the EU population, from healthy citizens to citizens suffering from food disorders, obesity or allergies.

Eligibility criteria:
The contest will be open to any legal entity (including single persons) or groups of legal entities from Member States and countries associated to Horizon 2020. Exclusion criteria foreseen in the provisions of articles 106(1), 107, 108 and 109 of the Financial Regulation (regulation 966/2012) will apply.

General/essential award criteria: The prize will be awarded, after closure of the contest, to the contestants who in the opinion of the jury demonstrate a solution (which is at least a system prototype demonstrated in an operational environment) that best addresses the following cumulative criteria:

- The solution is developed by the contestant.
- As a minimum, the solution is able to analyse: energetic value, ingredients, nutrients, substances or products causing allergies or intolerances, and chemicals (in particular pesticides) in food.
- Completeness, correctness, sensitivity and accuracy of information demonstrated by the solution to enable the user to make informed choices.
- User experience, (including user interface, response time, portability and intelligence) demonstrated by the solution.

---

60 The launch of the contest is subject to the availability of appropriations following the vote of the budget for the year 2015.

61 On its 'participant portal' (http://ec.europa.eu/research/participants/portal/page/home) but also actively publicised elsewhere to maximise participation


63 Further clarification of these criteria will be published in the Rules of Contest
Safety of the solution for human use.
- Openness and ability of the solution to integrate the food intake data with other available lifestyle data.
- Evidence of commercial readiness and accessibility to a wide range of users

Indicative timetable of contest(s):

<table>
<thead>
<tr>
<th>Stages</th>
<th>Date and time or indicative period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication of the contest</td>
<td>First quarter – 2015</td>
</tr>
<tr>
<td>Deadline for submission of proposals</td>
<td>Fourth quarter – 2015</td>
</tr>
<tr>
<td>Solutions demonstration</td>
<td>First quarter – 2016</td>
</tr>
<tr>
<td>Award decision</td>
<td>Second quarter – 2016</td>
</tr>
</tbody>
</table>

Type of action: Inducement prize

The common Rules of Contest for Prizes are provided in part F of the General Annexes.

Indicative budget: EUR 1 million from the 2015 budget.

**HOA 8 – 2015: Inducement Prize**

An innovative test to reduce the use of antibiotics in the management of upper respiratory tract infection.

This inducement prize will reward a rapid test that can identify at the point of care patients with upper respiratory tract infections that can safely be managed without antibiotics. In this context "Upper Respiratory Tract Infections" include pharyngitis, sinusitis, otitis as well as bronchitis.

The specific rules of the contest will be published in 2015 by the European Commission, which will directly launch and manage the contest and award the prize based on the judgement of independent experts.

The objectives pursued by this inducement prize are the following:

- To reduce the unnecessary use of antibiotics in case of viral upper respiratory tract infections;

---

64 The launch of the contest is subject to the availability of appropriations following the vote of the budget for the year 2015.

65 On its 'participant portal' (http://ec.europa.eu/research/participants/portal/page/home) but also actively publicised elsewhere to maximise participation.
− To reduce costs and side effects linked to the use of antibiotics;

− To delay the emergence of antibiotic resistant organisms;

− To enable health-care providers to take early decisions in the management of upper respiratory tract infections (rapid initiation and cessation of treatment) and to facilitate the health care provider’s decision not to prescribe antibiotics in case of viral infections and to facilitate patients’ acceptance of not taking antibiotics for viral infections;

− To tackle the widespread and significant health care issue of respiratory infections; an ageing population, antibiotic resistance and increasing health care costs make this a particularly challenging problem.

Expected results: development of a rapid point of care test that will reduce the use of antibiotics in a safe way in patients with upper respiratory tract infections.

Indicative timetable of contest(s):

<table>
<thead>
<tr>
<th>Stages</th>
<th>Date and time or indicative period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication of the contest</td>
<td>First quarter – 2015</td>
</tr>
<tr>
<td>Mandatory registration of participants</td>
<td>Third quarter – 2015</td>
</tr>
<tr>
<td>Deadline for submission of proposals</td>
<td>Second or third quarter – 2016</td>
</tr>
<tr>
<td>Evaluation of proposals</td>
<td>Third quarter – 2016</td>
</tr>
<tr>
<td>Award decision</td>
<td>Fourth quarter – 2016</td>
</tr>
</tbody>
</table>

Eligibility criteria: The contest is open to any legal entity (including natural persons) or group of legal entities established in an EU Member State or in a country associated to Horizon 2020.


General/essential award criteria: The prize will be awarded, after closure of the contest, to the entry that in the opinion of the jury demonstrates a solution that best addresses the following cumulative criteria67. Note that the solution should be both developed by the contestant and be novel.


67 Subject to further clarification in the contest rules which will be released at contest launch.
− Potential to reduce the use of antibiotics and magnitude of antibiotic use reduction: applicants should include a robust estimation of the antibiotic courses that are not given in cases of upper respiratory tract infections;

− Accuracy and safety: applicants should provide a risk/benefit analysis of giving or not giving antibiotics in the case of upper respiratory tract infections;

− Minimal/non-invasive;

− Low cost and affordable;

− Rapid;

− Easy to use.

Type of action: Inducement prize

The common Rules of Contest for Prizes are provided in part F of the General Annexes.

Indicative budget: EUR 1 million from the 2015 budget.

**Budget**

<table>
<thead>
<tr>
<th>Calls</th>
<th>2014 Budget EUR million</th>
<th>2015(^9) Budget EUR million</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call H2020-PHC-2014/15 Personalising health and care</td>
<td>549.30(^{10}) of which 451.10 from 08.020301 and 98.20 from 09.040301</td>
<td>543.50 of which 439.00 from 08.020301 and 104.50 from 09.040301</td>
</tr>
<tr>
<td>Call H2020-HCO-2014/5 Co-ordination activities</td>
<td>40.00 of which 36.00 from 08.020301 and 4.00 from 09.040301</td>
<td>29.00 from 08.020301</td>
</tr>
</tbody>
</table>

---

\(^{68}\) The budget figures given in this table are rounded to two decimal places.

\(^{69}\) The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.

\(^{70}\) To which EUR 5 million from the societal challenge ‘Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy’ (budget line 08.020302) will be added making a total of EUR 554.30 million for this call.
Contribution from this societal challenge to call ‘H2020-FTIPilot-2015’ (under Part 18 of the work programme) | 17.30
| of which 14.70 from 08.020301 and 2.60 from 09.040301

### Other Actions

<table>
<thead>
<tr>
<th>Description</th>
<th>2014 Budget EUR million</th>
<th>2015 Budget EUR million</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experts (expert evaluators, experts groups, monitors)</td>
<td>7.83</td>
<td>7.89</td>
</tr>
<tr>
<td>of which 6.00 from 08.020301 and 1.74 from 09.040301 and 0.09 from 09.045001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subscription – Human frontier science programme</td>
<td>4.77</td>
<td>4.86</td>
</tr>
<tr>
<td>from 08.020301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenders for programme evaluation, studies and impact assessment; and for conferences, events and outreach activities</td>
<td>4.70</td>
<td>3.65</td>
</tr>
<tr>
<td>of which 3.00 from 08.020301 and 1.70 from 09.040301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identified beneficiary - Presidency conferences</td>
<td>0.30</td>
<td>0.30</td>
</tr>
<tr>
<td>from 09.040301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subscription – Global alliance for Chronic Disease</td>
<td>0.18</td>
<td></td>
</tr>
<tr>
<td>from 08.020301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identified beneficiary – University of Edinburgh UK – Stem cell research outreach</td>
<td>0.60</td>
<td></td>
</tr>
<tr>
<td>from 08.020301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eHealth sectoral prize</td>
<td></td>
<td>1.00</td>
</tr>
<tr>
<td>From 09.040301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inducement prize</td>
<td></td>
<td>1.00</td>
</tr>
<tr>
<td>From 08.020301</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated total budget</td>
<td>607.68</td>
<td>608.50</td>
</tr>
</tbody>
</table>

---

71. The budget figures given in this table are rounded to two decimal places.

72. The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.
**Contribution to Horizontal activities (08.020500)**

<table>
<thead>
<tr>
<th>Activity</th>
<th>2014 Budget EUR million&lt;sup&gt;73&lt;/sup&gt;</th>
<th>2015&lt;sup&gt;74&lt;/sup&gt; Budget EUR million</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dissemination activities</td>
<td>0.73</td>
<td>0.77</td>
</tr>
<tr>
<td>(see Part 17 of the work programme)</td>
<td>of which 0.62 from 08.020301 and 0.11 from 09.040301</td>
<td>of which 0.65 from 08.020301 and 0.12 from 09.040301</td>
</tr>
<tr>
<td>Corporate communication</td>
<td>0.39</td>
<td>_</td>
</tr>
<tr>
<td>(see Part 17 of the work programme)</td>
<td>of which 0.33 from 08.020301 and 0.06 from 09.040301</td>
<td>_</td>
</tr>
<tr>
<td>Estimated total budget for horizontal activities</td>
<td>1.12</td>
<td>0.77</td>
</tr>
</tbody>
</table>

| Estimated total budget including horizontal activities | 608.80 | 609.27 |

---

<sup>73</sup> The budget figures given in this table are rounded to two decimal places.

<sup>74</sup> The budget amounts for 2015 are subject to the availability of the appropriations provided for in the draft budget for 2015 after the adoption of the budget 2015 by the budgetary authority or, if the budget is not adopted, as provided for in the system of provisional twelfths.